Buyers Guide 2023 by Physicians Office Resource

Resources for You, Your Patients, & Your Practice 2023 BUYERS GUIDE

Resilience

We make diagnostics that matter

© 2022 SEKISUI Diagnostics, LLC. All rights reserved. OSOM® is a registered trademark of SEKISUI Diagnostics, LLC. Because every result matters ™ is a trademark of SEKISUI Diagnostics, LLC. OSOM® ULTRA STREP A TEST OSOM® ULTRAPLUS FLU A&B TEST OSOM® MONO TEST We recognize your passion for providing the best care to your patients and helping them

and healthy life, but we also know you must navigate through daily challenges

your practice which requires resilience.

2200 2202 2201

+ Passion

lead a long

At SEKISUI Diagnostics

are committed to providing high-quality, U.S. made respiratory rapid tests which are accurate and easy-to-use so you can get the answers fast and your patients back to doing what they love. Like you, we understand there is a patient behind every answer—and that’s what matters most. For more information, call 888-616-0537, Option 2, or visit us at osomtests.com

Getting the most from this guide

There are two simple ways to request information about the products and services found in Physicians Office Resource.

1. Go to www.PhysiciansOfficeResource.com and enter the four-digit reference number found next to the product or service into the search field, then request additional information, schedule a demo, or speak with a sales agent all with just a simple click of a button.

2. Find the Business Reply Card in this issue, circle the desired reference numbers, complete the form, and drop into any USPS mailbox. A representative will contact you as quickly as possible to answer your questions.

www.PhysiciansOfficeResource.com

PUBLISHED BY Medical Education Resources, LLC

PUBLISHER

Aaron R. Medaris amedaris@physiciansofficeresource.com

CEO Andrew C. Nimmo acnimmo@physiciansofficeresource.com

PRESIDENT John D. Pasquale jpasquale@pharmaconnect.com

BUSINESS MANAGER Marci J. Hills mhills@physiciansofficeresource.com

TRAVEL EDITOR Brandi L. Brower

EDITORIAL BOARD

Michael Paquin, FHIMSS Barry Craig, MLT (NCA), CLC

STAFF WRITER

Dylan J. Chadwick

CREATIVE DIRECTOR PRODUCTION MANAGER

Jessica Elmer

To continue your free subscription of Physicians Office Resource magazine, please fill out the Business Reply Card (BRC) located within this magazine and drop in any United States Post Office mailbox.

If you are a manufacturer of medical products or provide services to medical professionals and would like to advertise your products or services to the nation’s top physicians doing in-office testing, call 801-380-6094 or visit: POR.io for more information.

2023 BUYERS GUIDE | 3

4 | PHYSICIANS OFFICE RESOURCE 2023 BUYERS GUIDE WHAT’S IN THIS GUIDE 6 2023 Medical Conferences 10 Diagnostics and Device Company Directory 14 Health Agency Hotlines 16 Government Organizations 17 MDescapes 20 State Medical Associations 22 Companies by Category 31 Product Guide

POC-22-NAM-3308 Comprehensive diabetes-management solutions at the point-of-care

insights

your

and drive

recommended

glycemic

routine urinalysis

Total U.S. Population with Diabetes The Prevalence of Diabetes Among U.S. Adults is on the Rise1 Help your patients reverse the trend Customize your patient consultations to enhance physician-patient partnership toward improved outcomes. siemens-healthineers.us/chronicdisease 1. Rowley, William R et al. “Diabetes 2030: Insights from Yesterday, Today, and Future Trends.” Population health management vol. 20,1 (2017): 6-12. doi:10.1089/pop.2015.0181. 2015 11.1% 35,644,000 2020 13.0% 43,271,000 2030 Projected 15.3% 54,913,000 54% Increase 2203 2204

Meet the Quadruple Aim in Diabetes Care with In-office HbA1c and uACR Better outcomes. Lower costs. Better patient experience. Better clinician experience.

Gain key

into

patient’s current status

guideline

test adherence: DCA Vantage® Analyzer CLIA-waived HbA1c • Rapid assessment for

control CLINITEK Status® Connect System CLIA-waived analyzer for

• Rapid kidney health assessment: CLINITEK® Microalbumin 2 Strip Albumin-to-creatinine ratio (ACR)

MEDICAL CONFERENCES

JANUARY

CANS Annual Meeting 2023 California Association of Neurological Surgeons

January 13 - 15, 2023 Riverside, CA 916-457-2267 www.cans1.org

SCCM Critical Care Congress Society of Critical Care Medicine

January 21 – 24, 2023 San Francisco, CA 847-827-6888 www.sccm.org

STS Annual Meeting Society of Thoracic Surgeons

Biophysical Society Annual Meeting 2023 Biophysical Society February 18 – 22, 2023 San Diego, CA 240-290-5600 www.biophysics.org/ 2023meeting#/

SIR 2023 Annual Scientific Meeting Society of Interventional Radiology

March 4 – 9, 2023 Phoenix, AZ 800-488-7284 www.SIRmeeting.org

American Association for Hand Surgery 2023 Annual Meeting January 17 – 21, 2023 Miami, FL 978-927-8330 www.handsurgery.org

American Society for Reconstructive Microsurgery Annual Meeting 2023 January 20 – 24, 2023 Miami, FL 312-456-9579 www.microsurg.org

January 21 – 23, 2023 San Diego, CA 312-202-5800 www.sts.org

FEBRUARY Pri-Med South February 9 – 11, 2023 Ft. Lauderdale, FL 877-477-4633 www.pri-med.com

ORS 2023 Annual Meeting Orthopaedic Research Society

February 10 – 14, 2023 Dallas, TX 847-823-5770 www.ors.org

2023 AAAAI Annual Meeting American Academy of Allergy Asthma & Immunology February 24 – 27, 2023 San Antonio, TX 414-272-6071 www.annualmeeting. aaaai.org

MARCH

AAC 2023 Annual Scientific Session and Expo American College of Cardiology

March 4 – 6, 2023 New Orleans, LA 800-253-4636 https://accscientificsession.acc.org

AAOS Annual Meeting 2023 American Academy of Orthopaedic Surgeons March 7 –11, 2023 Las Vegas, NV 847-823-7186 www.aaos.org

AAD Annual Meeting 2023 American Academy of Dermatology

March 17 – 21, 2023 New Orleans, LA 866-503-7546 www.aad.org/meetings/annual-meeting

6 | PHYSICIANS OFFICE RESOURCE

| 2023 |

SAGES 2023 Annual Meeting Society of American Gastrointestinal Endoscopic Surgeons

March 19 – April 1, 2023 Montreal, QC 310-437-0544 www.sages2023. surgery

SSO 2023 Annual Cancer Symposium Society of Surgical Oncology

March 22 – 25, 2023 Boston, MA 847-427-1400 www.surgonc.org

AAPM Annual Meeting American Academy of Pain Medicine

March 23 – 26, 2023 Ft. Lauderdale, FL 847-375-4731 www.aapmannualmeeting.com

APRIL

AORN Global Surgical Conference & Expo 2023 Association of Perioperative Registered Nurses

April 1 – 4, 2023 San Antonio, TX 800-755-2676 www.aorn.org

ASAPS Aesthetic Meeting 2023 The American Society for Aesthetic Plastic Surgery April 19 – 23, 2023 Miami, FL 800-364-2147 www.surgery.org

ACP Internal Medicine Meeting 2023 American College of Physicians April 27 – 29, 2023 San Diego, CA 800-523-1546 https://annualmeeting.acponline.org/

SGO 2023 Annual Meeting on Women’s Cancer Society of Gynecologic Oncologists

March 25 – 28, 2023 Tampa, FL 312-235-4060 www.sgo.org

AMGA Annual Conference 2023 American Medical Group Association March 28 – 31, 2023 Chicago, IL 703-838-0033 www.amga.org

ASLMS 2023 Annual Conference American Society for Laser Medicine & Surgery April 13 – 16, 2023 Phoenix, AZ 877-258-6028 www.aslms.org

AACR Annual Meeting 2023 American Association of Cancer Research April 14 – 19, 2023 Orlando, FL 866-423-3965 www.aacr.org

AANS Annual Scientific Meeting 2023 American Association of Neurological Surgeons April 21 – 24, 2023 Los Angeles, CA 847-378-0500 www.aans.org

AAN Annual Meeting 2023 American Academy of Neurology April 22 – 27, 2023 Boston, MA 800-879-1960 www.aan.com

Pri-Med Southwest 2023 April 16 – 18, 2023 Houston, TX 877-774-6338 www.pri-med.com

2023 Annual HIMSS Conference & Exhibition Healthcare Information and Management Systems April 17 – 21, 2023 Chicago, FL 855-326-8342 www.himssconference.org

ARRS Annual Meeting 2023 American Roentgen Ray Society April 26 – 20, 2023 Honolulu, HI 866-940-2777 www.arrs.org

ASBS Annual Meeting 2023 American Society of Breast Surgeons April 26 – 30, 2023 Boston, MA 877-992-5470 www.breastsurgeons. org

ASNR Annual Meeting & The Foundation of the ASNR Symposium 2023 American Society of Neuroradiology April 29 – May 3, 2023 Chicago, IL 630-574-0220 www.asnr.org MAY

AACE 2023 Annual Scientific & Clinical Congress American Association of Clinical Endocrinologists May 4 – 6, 2023 Seattle, WA 904-353-7878 www.aace.com

AANA Annual Congress 2023 Arthroscopy Association of North America May 4 – 6, 2023 New Orleans, LA 847-292-2262 www.aana.org

2023 BUYERS GUIDE | 7

2023 MEDICAL CONFERENCES

AATS Annual Meeting 2023 American Association for Thoracic Surgery May 6 – 9, 2023 Los Angeles, CA 978-927-8330 www.aats.org

JUNE

BIO International Convention 2023 Biotechnology Industry Organization

June 5 – 8, 2023 Boston, MA 202-962-6655 bio.org/

JULY

Pri-Med West 2023 July 13 – 15, 2023 Anaheim, CA 877-774-6338 www.pri-med.com

ACR Annual Meeting 2023 American College of Radiology May 6 – 10, 2023 Washington, DC 800-243-7419 www.acr.org/annual-meeting

ACOG 2023 Annual Clinical and Scientific Meeting American College of Obstetricians and Gynecologists May 19 – 21, 2023 Baltimore, MD 800- 673-8444 www.acog.org

ATS 2023 International Conference

American Thoracic Society May 19 – 24, 2023 Washington, DC 212-315-8600 conference.thoracic. org

ACSM Annual Meeting

American College of Sports Medicine May 30 – June 2, 2023 Denver, CO 317-637-9200 www.acsm.org/annual-meeting/annual-home

AMA Annual Meeting of House of Delegates 2023 American Medical Association June 10 – 14, 2023 Chicago, Illinois 800-621-8335 www.ama-assn.org

AACC 2023 Annual Meeting & Clinical Lab Expo American Association for Clinical Chemistry July 23 – 27, 2023 Anaheim, CA 800-892-1400 www.aacc.org

OCTOBER

ASTRO Annual Meeting 2023 American Society for Therapeutic Radiology & Oncology

October 1 – 4, 2023 San Diego, CA 703-502-1550 www.astro.org

ENDO Annual Meeting 2023

The Endocrine Society June 11 – 14, 2023 Atlanta, GA 888-363-6274 www.endocrine.org

AAPM Annual Meeting 2023 American Association of Physicists in Medicine July 23 – 27, 2023 Houston, TX 571-298-1300 www.aapm.org

CHEST 2023 ACCP Annual Meeting American College of Chest Physicians October 8 –11, 2023 Honolulu, HI 800-343-2227 www.chestnet.org

SNMMI 2023 Annual Meeting Society of Nuclear Medicine & Molecular Imaging June 24 – 27, 2023 Chicago, IL 703-708-9000 www.snmmi.org

APIC Annual Conference 2023 Association for Professional in Infection Control and Epidemiology

June 26 – 28, 2023 Orlando, FL 202-789-1890 annual.apic.org

PDA Annual Meeting Pacific Dermatologic Association July 27 – 30, 2023 San Francisco, CA 888-388-8815 www.pacificderm.org

AUGUST

No Conferences listed for August

SEPTEMBER

CNS Annual Meeting 2023 Congress of Neurological Surgeons September 9 – 13, 2023 Washington, DC 847-240-2500 www.cns.org

ACEP Annual Scientific Assembly 2023 American College of Emergency Physicians October 9 – 12, 2023 Philadelphia, PA 800-798-1822 www.acep.org

The ANESTHESIOLOGY 2023 Annual Meeting American Society of Anesthesiologists October 13 – 17, 2023 San Francisco, CA 847-825-5586 www.asahq.org

ASRM Scientific Congress and Expo 2023 American Society for Reproductive Medicine October 14 – 18, 2023 New Orleans, LA 205-978-5000 www.asrm.org

8 | PHYSICIANS OFFICE RESOURCE

2023 MEDICAL CONFERENCES

ISPE Annual Meeting

2023 International Society for Pharmaceutical Engineering

October 15 – 18, 2023 Las Vegas, NV 301-364-9201 www.ispe.org

NASS 2023 Annual Meeting

North American Spine Society

October 18 – 21, 2023 Los Angeles, CA 630-230-3600 www.spine.org

FMX 2023

American Academy of Family Physicians October 26 – 30, 2023 Chicago, IL 800-274-2237 www.aafp.org

NOVEMBER

ASHG 2023

American Society of Human Genetics

November 1 – 5, 2023 Washington, DC 301-634-7300 www.ashg.org

AAO Annual Meeting

2023 American Academy of Ophthalmology November 3 – 6, 2023 San Francisco, CA 415-561-8500 www.aao.org

ACAAI 2023 Annual Meeting

American College of Allergy Asthma & Immunology

November 10 – 14, 2023 Louisville, KY 847-427-1200 www.acaai.org

RSNA 2023 Scientific Assembly and Annual Meeting

Radiological Society of North America November 26 – 30, 2023 Chicago, Illinois 800-381-6660 www.rsna.org

DECEMBER No Conferences listed for December

2023 BUYERS GUIDE | 9 MOBILE DEVICES! • Latest Technology • Convenient • Affordable • Ultra Portable • User Friendly • Made in USA For Androids, iPads, iPhones and Tablets! EMR Compatable 12 Lead EKG with Interpretation (For iPad, iPhone & other Devices) Contact us for a special offer: 877.646.3300 // medicaldevicedepot.com Manufactured in USA by: (PC/Laptop and Mobile Devices sold seperately) New iPad EKG 12 Lead iPhone EKG w/ interp. EKG for iPad and iPhone Also works with WINDOWS, MAC, Andorid and tablets © 2015 Nasiff Associates. All rights reserved. CardioSuite, CardioCard, CardioECG, CardioStress, CardioHolter, CardioVitals, CardioMedical Center, CardioCard Mobile and Cardio Universal EMR Interface are trademarks of Nasiff Associates.

2023 MEDICAL CONFERENCES 2205

HEALTH AGENCY HOTLINES

Adoption National Adoption Center www.adopt.org (800) 862-3678

Aging National Aging Info and Referral Support Center www.nasuad.org (202) 898-2578

Alcohol Abuse Al-Anon Family Groups www.al-anon.alateen.org (757) 563-1600

Allergy/Asthma American Academy of Allergy, Asthma & Immunology www.aaaai.org (414) 272-6071

FARE/ Food Allergy Research & Education www.foodallergy.org (800) 929-4040

Alzheimer’s Disease Alzheimer’s Association www.alz.org (800) 272-3900

Anemia Aplastic Anemia & MDS International Foundation www.aamds.org (800) 747-2820

Sickle Cell Disease Association of America, Inc. www.sicklecelldisease. org (800) 421-8453

Arthritis Arthritis Foundation Info Hotline www.arthritis.org (844) 571-4357

Bladder Diseases Interstitial Cystitis Association www.ichelp.org (703) 442-2070

Blood Disorders National Hemophilia Foundation www.hemophilia.org (212) 328-3700

Bone Marrow National Bone Marrow Transplant Link www.nbmtlink.org (800) 546-5268

Bone Disease National Institute of Arthritis & Musculoskeletal & Skin Diseases www.niams.nih.gov (877) 226-4267

Breast Disease National Breast & Cervical Cancer Early Detection Program www.cdc.gov/cancer/ nbccedp (800) 232-4636

Digestive Disorders/ Diseases Crohn’s & Colitis Foundation of America www.ccfa.org (800) 932-2423

Celiac Disease Foundation www.celiac.org (818) 716-1513

Eating Disorders National Eating Disorders Association www.nationaleatingdisorders.org (800) 931-2237

Eye Disease American Macular Degeneration Foundation www.macular.org (888) 622-8527

The Vision Council www.thevisioncouncil. org (866) 826-0290

Glaucoma Research Foundation www.glaucoma.org (415) 986-3162

Fibromyalgia National Fibromyalgia Association www.fmaware.org

Gastrointestinal Diseases International Foundation for Functional Gastrointestinal Disorders www.iffgd.org (414) 964-1799

Growth Disorders Human Growth Foundation www.hgfound.org (800) 451-6434

Hearing Disorders International Hearing Society www.ihsinfo.org (734) 522-7200

Heart Disease American Heart Association www.heart.org (800) 242-8721

Hepatitis C Hepatitis C Association www.hepcassoc.org (908) 769-8479

14 | PHYSICIANS OFFICE RESOURCE

Hospital/Hospice Care Caring Connections www.caringinfo.org (703) 837-1500

Immunization National Immunization Hotline www.cdc.gov/vaccines (800) 232-4636

Impotence American Urological Association www.auanet.org (866) 746-4282

Insurance/Medicare/ Medicaid Medicare Issues Hotline www.medicare.gov (800) 633-4227

Kidney Disease National Kidney Foundation www.kidney.org (800) 622-9010

Lead EPA Lead Information Center www.epa.gov/lead (800) 424-5323

Liver Diseases American Liver Foundation www.liverfoundation.org (212) 668-1000

Lung Disease/Asthma/ Allergy American Lung Association www.lungusa.org (800) 586-4872

Mental Health Mental Health America www.mentalhealthamerica. net (800) 969-6642

Minority Health US Department of Health and Human Services Office of Minority Health www.minorityhealth.hhs. gov (800) 444-6472

Nervous System Disease American Parkinson Disease Association www.apdaparkinson.org (800) 223-2732

Multiple Sclerosis Foundation www.msfocus.org (888) 673-6287

National Stroke Association www.stroke.org (800) 242-8721

Organ Donation Living Bank www.livingbank.org (800) 528-2971

Pancreatic Disease Pancreatic Cancer Action Network www.pancan.org (877) 573-9971

Paralysis and Spinal Injury Christopher & Dana Reeve Foundation www.christopherreeve.org (800) 539-7309

Parkinson’s Disease Parkinson’s Disease oundation www.parkinson.org (800) 473-4636

Pediatrics American Academy of Pediatrics www.aap.org (800) 433-9016

Poison Control American Association of Poison Control Centers www.aapcc.org (800) 222-1222

Professionals American Medical Association www.ama-assn.org (800) 622-3211

Rehabilitation National Rehabilitation Info. Ctr. www.naric.com (800) 346-2742

Rheumatic Diseases Scleroderma Foundation www.scleroderma.org (800) 722-4673

Sexually Transmitted Diseases

CDC Sexually Transmitted Diseases Info. www.cdc.gov/std/ (800) 232-4636

Skin Disease National Psoriasis Foundation www.psoriasis.org (800) 723-9166

Spinal Diseases National Scoliosis Foundation, Inc. www.scoliosis.org (800 )673-6922

Stroke National Stroke Association www.stroke.org (800) 242-8721

Sudden Infant Death Syndrome

American SIDS Institute www.sids.org (239) 431-5425

Surgery/Facial Plastic Surgery

American Society of Plastic Surgeons www.plasticsurgery.org (847) 228-9900

Thyroid Disease American Thyroid Association www.thyroid.org (703) 998-8890

Veterans Veterans Special Issue Helpline Department of Veterans Affairs www.va.gov (844) 698-2311

VA Suicide Prevention www.mentalhealth.va.gov (844) 698-2311

Vision Disorders American Council of the Blind www.acb.org (800) 424-8666

2023 BUYERS GUIDE | 15

HEALTH AGENCY HOTLINES

GOVERNMENT ORGANIZATIONS

Agency for Healthcare Research and Quality (301) 427-1104 www.ahrq.gov

Center for Disease Control and Prevention (800) 232-4636 www.cdc.gov

Centers for Medicare & Medicaid Services (800) 633-4227 www.cms.gov

National Institute on Aging (800) 222-2225 www.nia.nih.gov

National Institute on Alcohol Abuse and Alcoholism (NIAAA) (301) 443-2857 www.niaaa.nih.gov

National Institute of Allergy and Infectious Diseases (866) 284-4107 www.niaid.nih.gov

National Institute of Arthritis and Musculoskeletal and Skin Disease (877) 226-4267 www.niams.nih.gov

National Institute of Biomedical Imaging and Bioengineering (301) 496-8859 www.nibib.nih.gov

National Institute of Child Health & Human Development (800) 370-2943 www.nichd.nih.gov

National Institute of Dental and Craniofacial Research (866) 232-4528 www.nidcr.nih.gov

National Institute of Diabetes and Digestive and Kidney Disease (800) 860-8747 www.niddk.nih.gov

National Institute of Environmental Health Sciences (919) 541-3345 www.niehs.nih.gov

National Institute of Mental Health (866) 615-6464 www.nimh.nih.gov

National Institute of Nursing Research (301) 496-0207 www.ninr.nih.gov

National Institute on Drug Abuse (301) 443-1124 www.drugabuse.gov

National Institutes of Health (301) 496-4000 www.nih.gov

Occupational Safety & Health Administration (800) 321-6742 www.osha.gov

U.S. Department of Health & Human Services (877) 696-6775 www.hhs.gov

U.S. National Library of Medicine (301) 496-6308 www.nlm.nih.gov

16 | PHYSICIANS OFFICE RESOURCE

— PHYSICIANSOFFICERESOURCE.COM/MDESCAPES/ INSTAGRAM @MDESCAPES LUXURY TRAVEL DESTINATIONS | SPECIAL OFFERS | REVIEWS

18 | PHYSICIANS OFFICE RESOURCE

MDescapes features exclusive luxury travel discounts and offers! Our goal is to reward you, the healthcare professional, and help provide the rest, adventure, and memoires that accompany a luxury vacation.

2023 BUYERS GUIDE | 19

REWARD YOU

Our goal is to

— FIND YOUR ESCAPE AT PhysiciansOfficeResource.com/MDescapes FOUR SEASONS NEVIS FOUR SEASONS PUNTA MITA FOUR SEASONS NEW ORLEANS FOUR SEASONS SANTA FE CARTON HOUSE SANDESTIN GOLF AND BEACH RESORT AND MORE

STATE MEDICAL ASSOCIATIONS

Alabama www.alamedical.org (800) 239-6272

Alaska www.asmadocs.org (907) 562-0304

Arizona www.azmed.org (602) 347-6900

Arkansas www.arkmed.org (501) 224-8967

California www.cmanet.org (800) 786-4262

Colorado www.cms.org (720) 859-1001

Connecticut www.csms.org (203) 865-0587

District of Columbia www.msdc.org (202) 466-1800

Delaware www.medsocdel.org (302) 366-1400

Florida www.flmedical.org (850) 224-6627

Georgia www.mag.org (678) 303-9290

Hawaii www.hawaiimedicalassociation.org (808) 536-7702

Idaho www.idmed.org (208) 344-7888

Illinois www.isms.org (800) 782-4767

Indiana www.ismanet.org (800) 257-4762

Iowa www.iowamedical.org (515) 223-1401

Kansas www.kmsonline.org (800) 332-0156

Kentucky www.kyma.org (502) 426-6200

Louisiana www.lsms.org (225) 763-8500

Maine www.mainemed.com (207) 622-3374

Maryland www.medchi.org (800) 492-1056

Massachusetts www.massmed.org (781) 893-4610

Michigan www.msms.org (517) 337-1351

Minnesota www.mnmed.org (612) 378-1875

Mississippi www.msmaonline.com (601) 853-6733

Missouri www.msma.org (573) 636-5151

Montana www.mmaoffice.org (406) 443-4000

Nebraska www.nebmed.org (402) 474-4472

Nevada www.nvdoctors.org (775) 825-6788

New Hampshire www.nhms.org (603) 224-1909

New Jersey www.msnj.org (609) 896-1766

New Mexico www.nmms.org (505) 828-0237

New York www.mssny.org (516) 488-6100

North Carolina www.ncmedsoc.org (919) 833-3836

North Dakota www.ndmed.org (701) 223-9475

Ohio www.osma.org (800) 766-6762

Oklahoma www.okmed.org (800) 522-9452

Oregon www.theoma.org (503) 619-8000

Pennsylvania www.pamedsoc.org (800) 228-7823

Rhode Island www.rimed.org (401) 331-3207

South Carolina www.scmedical.org (800) 327-1021

South Dakota www.sdsma.org (605) 336-1965

Tennessee www.tnmed.org (615) 385-2100

Texas www.texmed.org (800) 880-1300

Utah www.utahmed.org (801) 747-3500

Vermont www.vtmd.org (802) 223-7898

Virginia www.msv.org (800) 746-6768

Washington www.wsma.org (206) 441-9762

West Virginia www.wvsma.org (304) 925-0342

Wisconsin www.wisconsinmedicalsociety.org (608) 442-3800

Wyoming www.wyomed.org (307) 635-2424

20 | PHYSICIANS OFFICE RESOURCE

2206

PRODUCT CATEGORIES

A1C

Abbott www.globalpointofcare. abbott

Hemocue America www.Hemocue.com

Siemens Healthcare Diagnostics www.siemens-healthineers.com

ABI Huntleigh Diagnostics www.huntleigh-diagnostics.com

Medical Device Depot www.medicaldevicedepot.com

Newman Medical www.newman-medical. com

ACNE TREATMENT Theravant Corp www.theraclear.com

AESTHETICS

Aerolase www.aerolase.com

Alma Lasers www.almalasers.com

Cutera www.cutera.com

CryoProbe www.ho-equipments.com

DermaMed www.dermamedsolutions. com

Orasure Histofreezer www.histofreezer.com

Premier Medical Products www.premusa.com

ALBUMIN Siemens Healthcare Diagnostics www.siemens-healthineers.com

ALLERGY Jant Pharmacal www.accutest.net

Jant Pharmacal www.medicaldevicedepot.com

Asthma Testing Micro Direct www.mdspiro.com

Vitalograph www.vitalograph.com

AUDIOMETRY Ototronix www.ototronixdiagnostics.com

AUGMENTED MEDICINE Medpod www.medpodhealth.com

BLOOD GAS

Abbott Point of Care www.globalpointofcare. abbott

Nova Biomedical www.novabiomedical.com

BLOOD PRESSURE Medical Device Depot www.medicaldevicedepot.com

Vitalograph www.vitalograph.com

Welch Allyn www.welchallyn.com

BONE HEALTH Bone Index Ltd. www.bindex.us

Brain Assesment Evoke Neuroscience www.evokeneuroscience. com

Morningside Medical Equipment www.morningsidemedicalequipment.com

CARDIO VASCULAR/ PULMONARY Abbott Rapid Diagnostics www.globalpointofcare. abbott

Brilliant Medical www.brilliantmedical.com

Futuremed America, Inc. www.futuremedamerica. com

Medical Device Depot www.medicaldevicedepot.com

Micro Direct, Inc. www.mdspiro.com

Midmark Diagnostics, Inc. www.midmark.com

MIR – Medical International Research www.spirometry.com

Nasiff Associates, Inc. www.nasiff.com

ndd Medical Technologies www.nddmed.com

Nihon Kohden www.nohonkohden.com

Nonin Medical www.nonin.com

Schiller America, Inc. www.schillerus.com

SDI Diagnostics Inc. www.sdidiagnostics.com Vitalograph www.vitalograph.com Welch Allyn www.welchallyn.com

Centrifuges Drucker Diagnostics www.druckerdiagnostics. com

CHEMISTRY ANALYZERS

Abbott Diagnostics www.corelaboratory. abbott

Abbott Point of Care www.globalpointofcare. abbott

AMS Diagnostics www.amsdiagnostics.com

Beckman Coulter www.beckmancoulter.com

Arkray www.arkrayusa.com

Carolina Liquid Chemistries, Inc. www.carolinachemistries. com

ELITech Group www.elitechgroup.com

22 | PHYSICIANS OFFICE RESOURCE

Horiba Medical www.horiba.com/us/en/ medical

Jant Pharmacal www.accutest.net

Medica Corporation www.medicacorp.com

Randox Laboratories, USA www.randox.com Roche www.roche.com

Sekisui www.sekisuidiagnostics. com

Vital Diagnostics www.vitaldiagnostics.com

CHOLESTEROL & TRIGLYCERIDE TESTING

Abbott www.globalpointofcare. abbott

Alfa Wassermann, Inc www.alfawassermannus. com Arkray www.arkrayusa.com

Beckman Coulter, Inc. www.beckman.com

Carolina Liquid Chemistries, Inc. www.carolinachemistries. com

Horiba Medical www.horiba.com/us/en/ medical

Medica Corporation www.medicacorp.com

PTS Diagnostics www.ptsdiagnostics.com

Randox Laboratories, Inc. www.randox.com

COAGULATION Roche www.roche.com

CONJUNCTIVITIS TESTS

RPS Diagnostics www.rpsdetectors.com

COVID-19 Tests BD https://bdveritor.bd.com/ en-us

bioMerieux www.biomerieux.com

LumiraDx www.lumiradx.com

Mercedes Scientific www.mercedesscientific. com Quidel www.quidel.com

CREATININE

Siemens Healthcare Diagnostics www.siemens-healthineers.com

CRYOSURGICAL DEVICES CryoProbe www.ho-equipments.com

CryoConcepts, LP www.cryoconcepts.com

DIABETES

Abbott www.globalpointofcare. abbott

Siemens Healthcare Diagnostics www.siemens-healthineers.com

DEFIBRILLATORS

Medical Device Depot www.medicaldevicedepot.com

Zoll www.zoll.com

DOPPLERS

Huntleigh Diagnostics www.huntleigh-diagnostics.com

Medical Device Depot www.medicaldevicedepot.com

Newman Medical www.newman-medical. com

Wallach Surgical Devices www.wallachsurgical.com

DRUGS OF ABUSE TESTS

Carolina Liquid Chemistries www.carolinachemistries. com

Horiba www.horiba.com/us/en/ medical

Laboratory Consulting, LLC www.urinedrugscreenconsulting.com

Randox Laboratories, Inc. www.randox.com Sekisui www.sekisuidiagnostics. com

EAR, NOSE & THROAT Bionix www.bionix.com

Brilliant Medical www.brilliantmedical.com

HEINE Optotechnik www.heine.com

Med-Electronics, Inc. www.med-electronics. com

Welch Allyn, Inc. www.welchallyn.com

ECG

Edan Diagnostics www.edandiagnostics. com

GE Healthcare Technologies www.gehealthcare.com

Medical Device Depot www.medicaldevicedepot.com

Midmark Diagnostics, Inc. www.midmark.com Mortara www.mortara.com Schiller America, Inc. www.schilleramerica.com

Vitalograph www.vitalograph.com Welch Allyn www.welchallyn.com

EDUCATION AAFP www.aafp.org COLA www.cola.org

ELECTROLYTE

Abbott Point of Care www.globalpointofcare. abbott Medica Corporation www.medicacorp.com

Opti Medical Systems, Inc. Roche www.roche.com

ENDOSCOPY

Pentax Medical www.pentaxmedical.com

E-PRESCRIBING

Amazing Charts www.amazingcharts.com DrFirst www.drfirst.com

ESR ALCOR Scientific www.alcorscientific.com

PRODUCT CATEGORIES

A1C

Abbott www.globalpointofcare. abbott

Hemocue America www.Hemocue.com

Siemens Healthcare Diagnostics www.siemens-healthineers.com

ABI Huntleigh Diagnostics www.huntleigh-diagnostics.com

Medical Device Depot www.medicaldevicedepot.com

Newman Medical www.newman-medical. com

ACNE TREATMENT Theravant Corp www.theraclear.com

AESTHETICS

Aerolase www.aerolase.com

Alma Lasers www.almalasers.com

Cutera www.cutera.com

CryoProbe www.ho-equipments.com

DermaMed www.dermamedsolutions. com

Orasure Histofreezer www.histofreezer.com

Premier Medical Products www.premusa.com

ALBUMIN Siemens Healthcare Diagnostics www.siemens-healthineers.com

ALLERGY

Jant Pharmacal www.accutest.net

Jant Pharmacal www.medicaldevicedepot.com

Asthma Testing Micro Direct www.mdspiro.com

Vitalograph www.vitalograph.com

AUDIOMETRY Ototronix www.ototronixdiagnostics.com

AUGMENTED MEDICINE Medpod www.medpodhealth.com

BLOOD GAS Abbott Point of Care www.globalpointofcare. abbott Nova Biomedical www.novabiomedical.com

BLOOD PRESSURE Medical Device Depot www.medicaldevicedepot.com

Vitalograph www.vitalograph.com

Welch Allyn www.welchallyn.com

BONE HEALTH Bone Index Ltd. www.bindex.us

Brain Assesment Evoke Neuroscience www.evokeneuroscience. com

Morningside Medical Equipment www.morningsidemedicalequipment.com

CARDIO VASCULAR/ PULMONARY Abbott Rapid Diagnostics

www.globalpointofcare. abbott

Brilliant Medical www.brilliantmedical.com

Futuremed America, Inc. www.futuremedamerica. com

Medical Device Depot www.medicaldevicedepot.com

Micro Direct, Inc. www.mdspiro.com

Midmark Diagnostics, Inc. www.midmark.com

MIR – Medical International Research www.spirometry.com

Nasiff Associates, Inc. www.nasiff.com

ndd Medical Technologies www.nddmed.com

Abbott Point of Care www.globalpointofcare. abbott

AMS Diagnostics www.amsdiagnostics.com

Beckman Coulter www.beckmancoulter.com Arkray www.arkrayusa.com

Carolina Liquid Chemistries, Inc. www.carolinachemistries. com

ELITech Group www.elitechgroup.com

Horiba Medical www.horiba.com/us/en/ medical

Jant Pharmacal www.accutest.net

Medica Corporation www.medicacorp.com

Nihon Kohden www.nohonkohden.com

Nonin Medical www.nonin.com

Schiller America, Inc. www.schillerus.com

SDI Diagnostics Inc. www.sdidiagnostics.com

Vitalograph www.vitalograph.com

Welch Allyn www.welchallyn.com

Centrifuges

Drucker Diagnostics www.druckerdiagnostics. com

CHEMISTRY ANALYZERS

Abbott Diagnostics www.corelaboratory. abbott

Randox Laboratories, USA www.randox.com Roche www.roche.com

Sekisui www.sekisuidiagnostics. com

Vital Diagnostics www.vitaldiagnostics.com

CHOLESTEROL & TRIGLYCERIDE TESTING Abbott www.globalpointofcare. abbott

Alfa Wassermann, Inc www.alfawassermannus. com Arkray www.arkrayusa.com

24 | PHYSICIANS OFFICE RESOURCE

Beckman Coulter, Inc. www.beckman.com

Carolina Liquid Chemistries, Inc. www.carolinachemistries. com

Horiba Medical www.horiba.com/us/en/ medical

Medica Corporation www.medicacorp.com

PTS Diagnostics www.ptsdiagnostics.com

Randox Laboratories, Inc. www.randox.com

COAGULATION Roche www.roche.com

CONJUNCTIVITIS TESTS

RPS Diagnostics www.rpsdetectors.com

COVID-19 Tests BD https://bdveritor.bd.com/ en-us

bioMerieux www.biomerieux.com

LumiraDx www.lumiradx.com

Mercedes Scientific www.mercedesscientific. com

Quidel www.quidel.com

CREATININE

Siemens Healthcare Diagnostics www.siemens-healthineers.com

CRYOSURGICAL DEVICES

CryoProbe www.ho-equipments.com

CryoConcepts, LP www.cryoconcepts.com

DIABETES

Abbott www.globalpointofcare. abbott

Siemens Healthcare Diagnostics www.siemens-healthineers.com

DEFIBRILLATORS

Medical Device Depot www.medicaldevicedepot.com Zoll www.zoll.com

DOPPLERS

Huntleigh Diagnostics www.huntleigh-diagnostics.com

Medical Device Depot www.medicaldevicedepot.com

Newman Medical www.newman-medical. com

Wallach Surgical Devices www.wallachsurgical.com

DRUGS OF ABUSE TESTS

Carolina Liquid Chemistries www.carolinachemistries. com

Horiba www.horiba.com/us/en/ medical

Laboratory Consulting, LLC www.urinedrugscreenconsulting.com

Randox Laboratories, Inc. www.randox.com

Sekisui www.sekisuidiagnostics.

com

EAR, NOSE & THROAT Bionix www.bionix.com

Brilliant Medical www.brilliantmedical.com

HEINE Optotechnik www.heine.com

Med-Electronics, Inc. www.med-electronics. com

Welch Allyn, Inc. www.welchallyn.com

ECG Edan Diagnostics www.edandiagnostics. com GE Healthcare Technologies www.gehealthcare.com

Medical Device Depot www.medicaldevicedepot.com

Midmark Diagnostics, Inc. www.midmark.com Mortara www.mortara.com

Schiller America, Inc. www.schilleramerica.com Vitalograph www.vitalograph.com

Welch Allyn www.welchallyn.com

EDUCATION AAFP www.aafp.org

COLA www.cola.org

ELECTROLYTE

Abbott Point of Care www.globalpointofcare. abbott Medica Corporation

www.medicacorp.com

Opti Medical Systems, Inc. Roche www.roche.com

ENDOSCOPY Pentax Medical www.pentaxmedical.com

E-PRESCRIBING Amazing Charts www.amazingcharts.com

DrFirst www.drfirst.com

ESR ALCOR Scientific www.alcorscientific.com

EXAM ROOM FURNITURE Brewer Medical www.brewercompany.com

Medical Device Depot www.medicaldevicedepot.com

Midmark Corporation www.midmark.com

Vinyl Crafters www.vcupholstery.com

FECAL OCCULT BLOOD Beckman Coulter, Inc. www.beckmancoulter.com

Clinical Genomics www.clinicalgenomics. com

Hemosure, Inc. www.hemosure.com

Jant Pharmacal www.accutest.net Sekisui www.sekisui.com

Flu testing BD https://bdveritor.bd.com/ en-us

2023 BUYERS GUIDE | 25

PRODUCT CATEGORIES

BATTLE TESTED IN EOS DISEASE

With

NUCALA is for the:

• add-on maintenance treatment of patients 6+ with SEA. Not for acute bronchospasm or status asthmaticus.

• add-on maintenance treatment of CRSwNP in patients 18+ with inadequate response to nasal corticosteroids.

• treatment of adult patients with EGPA.

• treatment of patients aged 12+ with HES for ≥6 months without an identifiable non-hematologic secondary cause.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

NUCALA should not be administered to patients with a history of hypersensitivity to mepolizumab or excipients in the formulation.

proven results across 4 indications— our track record stands out

Severe eosinophilic asthma

Eosinophilic granulomatosis with polyangiitis

Hypereosinophilic syndrome

Chronic rhinosinusitis with nasal polyps

(SEA)

(EGPA)

(HES)

(CRSwNP) Visit NucalaBattleTested.com

learn more

IMPORTANT SAFETY INFORMATION (cont’d)

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions (eg, anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred with NUCALA. These reactions generally occur within hours of administration but can have a delayed onset (ie, days). If a hypersensitivity reaction occurs, discontinue NUCALA.

Acute Asthma Symptoms or Deteriorating Disease

NUCALA should not be used to treat acute asthma symptoms, acute exacerbations, or acute bronchospasm.

Opportunistic Infections: Herpes Zoster

Herpes zoster infections have occurred in patients receiving NUCALA. Consider vaccination if medically appropriate.

Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with NUCALA. Decreases in corticosteroid doses, if appropriate, should be gradual and under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infection

Treat patients with pre-existing helminth infections before initiating therapy with NUCALA. If patients become infected while receiving NUCALA and do not respond to anti-helminth treatment, discontinue NUCALA until infection resolves.

ADVERSE REACTIONS

Most common adverse reactions (≥5%) in patients receiving NUCALA:

• Severe asthma trials: headache, injection site reaction, back pain, fatigue

• CRSwNP trial: oropharyngeal pain, arthralgia

• EGPA and HES trials (300 mg of NUCALA): no additional adverse reactions were identified to those reported in severe asthma clinical trials

Systemic reactions, including hypersensitivity, occurred in clinical trials in patients receiving NUCALA. Manifestations included rash, pruritus, headache, myalgia, flushing, urticaria, erythema, fatigue, hypertension, warm sensation in trunk and neck, cold extremities, dyspnea, stridor, angioedema, and multifocal skin reaction. A majority of systemic reactions were experienced the day of dosing.

USE IN SPECIFIC POPULATIONS

A pregnancy exposure registry monitors pregnancy outcomes in women with asthma exposed to NUCALA during pregnancy. To enroll call 1-877-311-8972 or visit www.mothertobaby.org/asthma.

The data on pregnancy exposures are insufficient to inform on drug-associated risk. Monoclonal antibodies, such as mepolizumab, are transported across the placenta in a linear fashion as the pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimesters.

Trademarks are owned by or licensed to the GSK group of companies.

Please see Brief Summary of Prescribing Information for NUCALA on the following pages.

MPLJRNA220004 August 2022 Produced in USA.

NUCALA (mepolizumab) for injection, for subcutaneous use

NUCALA (mepolizumab) injection, for subcutaneous use

The following is a brief summary only; see full prescribing information for complete product information.

1 INDICATIONS AND USAGE

1.1

Maintenance Treatment of Severe Asthma

NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype [see Use in Specific Populations (8.4) and Clinical Studies (14.1) of full prescribing information]

Limitations of Use

NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

1.2

Maintenance Treatment of Chronic Rhinosinusitis with Nasal Polyps

NUCALA is indicated for the add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.

1.3 Eosinophilic Granulomatosis with Polyangiitis

NUCALA is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

1.4

Hypereosinophilic Syndrome

NUCALA is indicated for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause.

4 CONTRAINDICATIONS

NUCALA is contraindicated in patients with a history of hypersensitivity to mepolizumab or excipients in the formulation [see Warnings and Precautions (5.1) and Description (11) of full prescribing information]

5 WARNINGS AND PRECAUTIONS

5.1

Hypersensitivity Reactions

Hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred following administration of NUCALA. These reactions generally occur within hours of administration, but in some instances can have a delayed onset (i.e., days). In the event of a hypersensitivity reaction, NUCALA should be discontinued [see Contraindications (4)]

5.2

Acute Asthma Symptoms or Deteriorating Disease

NUCALA should not be used to treat acute asthma symptoms or acute exacerbations. Do not use NUCALA to treat acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with NUCALA.

5.3 Opportunistic Infections: Herpes Zoster

Herpes zoster has occurred in subjects receiving NUCALA 100 mg in controlled clinical trials [see Adverse Reactions (6.1)]. Consider vaccination if medically appropriate.

5.4

Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids (ICS) abruptly upon initiation of therapy with NUCALA. Reductions in corticosteroid dosage, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dosage may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

5.5

Parasitic (Helminth) Infection

Eosinophils may be involved in the immunological response to some helminth infections. Patients with known parasitic infections were excluded from participation in clinical trials. It is unknown if NUCALA will influence a patient’s response against parasitic infections. Treat patients with pre-existing helminth infections before initiating therapy with NUCALA. If patients become infected while receiving treatment with NUCALA and do not respond to anti-helminth treatment, discontinue treatment with NUCALA until infection resolves.

6 ADVERSE REACTIONS

The following adverse reactions are described in greater detail in other sections:

• Hypersensitivity reactions [see Warnings and Precautions (5.1)]

• Opportunistic infections: herpes zoster [see Warnings and Precautions (5.3)] Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

6.1 Clinical Trials Experience in Severe Asthma

Adult

and Adolescent Patients Aged 12 Years and Older

A total of 1,327 patients with severe asthma were evaluated in 3 randomized, placebo-controlled, multicenter trials of 24 to 52 weeks’ duration (Trial 1, NCT01000506; Trial 2, NCT01691521; and Trial 3, NCT01691508). Of these, 1,192 had a history of 2 or more exacerbations in the year prior to enrollment despite regular use of high-dose ICS plus additional controller(s) (Trials 1 and 2), and 135 patients required daily oral corticosteroids (OCS) in addition to regular use of highdose ICS plus additional controller(s) to maintain asthma control (Trial 3). All

patients had markers of eosinophilic airway inflammation [see Clinical Studies (14.1) of full prescribing information]. Of the patients enrolled, 59% were female, 85% were White, and ages ranged from 12 to 82 years. Mepolizumab was administered subcutaneously or intravenously once every 4 weeks; 263 patients received NUCALA (mepolizumab 100 mg subcutaneous) for at least 24 weeks. Serious adverse events that occurred in more than 1 patient and in a greater percentage of patients receiving NUCALA 100 mg (n = 263) than placebo (n = 257) included 1 event, herpes zoster (2 patients vs. 0 patients, respectively). Approximately 2% of patients receiving NUCALA 100 mg withdrew from clinical trials due to adverse events compared with 3% of patients receiving placebo.

The incidence of adverse reactions in the first 24 weeks of treatment in the 2 confirmatory efficacy and safety trials (Trials 2 and 3) with NUCALA 100 mg is shown in Table 1.

Table 1. Adverse Reactions with NUCALA with ≥3% Incidence and More Common than Placebo in Patients with Severe Asthma (Trials 2 and 3)

Adverse Reaction

NUCALA (Mepolizumab 100 mg Subcutaneous) (n = 263) %

Placebo (n = 257) %

Headache 19 18

Injection site reaction 8 3 Back pain 5 4

Fatigue 5 4 Influenza 3 2

Urinary tract infection 3 2 Abdominal pain upper 3 2 Pruritus 3 2 Eczema 3 <1 Muscle spasms 3 <1

52-Week Trial: Adverse reactions from Trial 1 with 52 weeks of treatment with mepolizumab 75 mg intravenous (IV) (n = 153) or placebo (n = 155) and with ≥3% incidence and more common than placebo and not shown in Table 1 were: abdominal pain, allergic rhinitis, asthenia, bronchitis, cystitis, dizziness, dyspnea, ear infection, gastroenteritis, lower respiratory tract infection, musculoskeletal pain, nasal congestion, nasopharyngitis, nausea, pharyngitis, pyrexia, rash, toothache, viral infection, viral respiratory tract infection, and vomiting. In addition, 3 cases of herpes zoster occurred in patients receiving mepolizumab 75 mg IV compared with 2 patients in the placebo group.

Systemic Reactions, including Hypersensitivity Reactions: In Trials 1, 2, and 3 described above, the percentage of patients who experienced systemic (allergic and non-allergic) reactions was 3% in the group receiving NUCALA 100 mg and 5% in the placebo group. Systemic allergic/hypersensitivity reactions were reported by 1% of patients in the group receiving NUCALA 100 mg and 2% of patients in the placebo group. The most commonly reported manifestations of systemic allergic/ hypersensitivity reactions reported in the group receiving NUCALA 100 mg included rash, pruritus, headache, and myalgia. Systemic non-allergic reactions were reported by 2% of patients in the group receiving NUCALA 100 mg and 3% of patients in the placebo group. The most commonly reported manifestations of systemic non-allergic reactions reported in the group receiving NUCALA 100 mg included rash, flushing, and myalgia. A majority of the systemic reactions in patients receiving NUCALA 100 mg (5/7) were experienced on the day of dosing.

Injection Site Reactions : Injection site reactions (e.g., pain, erythema, swelling, itching, burning sensation) occurred at a rate of 8% in patients receiving NUCALA 100 mg compared with 3% in patients receiving placebo.

Long-term Safety : Nine hundred ninety-eight patients received NUCALA 100 mg in ongoing open-label extension studies, during which additional cases of herpes zoster were reported. The overall adverse event profile has been similar to the asthma trials described above.

Pediatric Patients Aged 6 to 11 Years

The safety data for NUCALA is based upon 1 open-label clinical trial that enrolled 36 patients with severe asthma aged 6 to 11 years. Patients received 40 mg (for those weighing <40 kg) or 100 mg (for those weighing ≥40 kg) of NUCALA administered subcutaneously once every 4 weeks. Patients received NUCALA for 12 weeks (initial short phase). After a treatment interruption of 8 weeks, 30 patients received NUCALA for a further 52 weeks (long phase). The adverse reaction profile for patients aged 6 to 11 years was similar to that observed in patients aged 12 years and older.

6.2 Clinical Trials Experience in Chronic Rhinosinusitis with Nasal Polyps

A total of 407 patients with CRSwNP were evaluated in 1 randomized, placebocontrolled, multicenter, 52-week treatment trial. Patients received NUCALA 100 mg or placebo subcutaneously once every 4 weeks. Patients had recurrent CRSwNP with a history of prior surgery and were on nasal corticosteroids for at least 8 weeks prior to screening [see Clinical Studies (14.2) of full prescribing information]. Of the patients enrolled, 35% were female, 93% were White, and ages ranged from 18 to 82 years. Approximately 2% of patients receiving NUCALA

(continued on next page) BRIEF SUMMARY

6 ADVERSE REACTIONS (cont’d)

100 mg withdrew from study treatment due to adverse events compared with 2% of patients receiving placebo. Table 2 summarizes adverse reactions that occurred in ≥3% of NUCALA-treated patients and more frequently than in patients treated with placebo in the CRSwNP trial.

Table 2. Adverse Reactions with NUCALA with ≥3% Incidence and More Common than Placebo in Patients with CRSwNP

Adverse Reaction

NUCALA (Mepolizumab 100 mg Subcutaneous) (n = 206) %

Placebo (n = 201) %

Oropharyngeal pain 8 5

Arthralgia 6 2

Abdominal Pain Upper 3 2 Diarrhea 3 2 Pyrexia 3 2 Nasal dryness 3 <1 Rash 3 <1

CRSwNP = Chronic Rhinosinusitis with Nasal Polyps.

Systemic Reactions, including Hypersensitivity

Reactions

In the 52-week trial, the percentage of patients who experienced systemic (allergic [type I hypersensitivity] and other) reactions was <1% in the group receiving NUCALA 100 mg and <1% in the placebo group. Systemic allergic (type I hypersensitivity) reactions were reported by <1% of patients in the group receiving NUCALA 100 mg and no patients in the placebo group. The manifestations of systemic allergic (type I hypersensitivity) reactions included urticaria, erythema, and rash and 1 of the 3 reactions occurred on the day of dosing. Other systemic reactions were reported by no patients in the group receiving NUCALA 100 mg and <1% of patients in the placebo group.

Injection Site Reactions

Injection site reactions (e.g., erythema, pruritus) occurred at a rate of 2% in patients receiving NUCALA 100 mg compared with <1% in patients receiving placebo.

6.3 Clinical Trials Experience in Eosinophilic Granulomatosis with Polyangiitis

A total of 136 patients with EGPA were evaluated in 1 randomized, placebo-controlled, multicenter, 52-week treatment trial. Patients received 300 mg of NUCALA or placebo subcutaneously once every 4 weeks. Patients enrolled had a diagnosis of EGPA for at least 6 months prior to enrollment with a history of relapsing or refractory disease and were on a stable dosage of oral prednisolone or prednisone of greater than or equal to 7.5 mg/day (but not greater than 50 mg/day) for at least 4 weeks prior to enrollment [see Clinical Studies (14.3) of full prescribing information]. Of the patients enrolled, 59% were female, 92% were White, and ages ranged from 20 to 71 years. No additional adverse reactions were identified to those reported in the severe asthma trials.

Systemic Reactions, including Hypersensitivity Reactions

In the 52-week trial, the percentage of patients who experienced systemic (allergic and non-allergic) reactions was 6% in the group receiving 300 mg of NUCALA and 1% in the placebo group. Systemic allergic/hypersensitivity reactions were reported by 4% of patients in the group receiving 300 mg of NUCALA and 1% of patients in the placebo group. The manifestations of systemic allergic/hypersensitivity reactions reported in the group receiving 300 mg of NUCALA included rash, pruritus, flushing, fatigue, hypertension, warm sensation in trunk and neck, cold extremities, dyspnea, and stridor. Systemic non-allergic reactions were reported by 1 (1%) patient in the group receiving 300 mg of NUCALA and no patients in the placebo group. The reported manifestation of systemic non-allergic reactions reported in the group receiving 300 mg of NUCALA was angioedema. Half of the systemic reactions in patients receiving 300 mg of NUCALA (2/4) were experienced on the day of dosing.

Injection Site Reactions

Injection site reactions (e.g., pain, erythema, swelling) occurred at a rate of 15% in patients receiving 300 mg of NUCALA compared with 13% in patients receiving placebo.

6.4 Clinical Trials Experience in Hypereosinophilic Syndrome

A total of 108 adult and adolescent patients aged 12 years and older with HES were evaluated in a randomized, placebo-controlled, multicenter, 32-week treatment trial. Patients with non-hematologic secondary HES or FIP1L1-PDGFR kinase-positive HES were excluded from the trial. Patients received 300 mg of NUCALA or placebo subcutaneously once every 4 weeks. Patients must have been on a stable dose of background HES therapy for the 4 weeks prior to randomization [see Clinical Studies (14.4) of full prescribing information]. Of the patients enrolled, 53% were female, 93% were White, and ages ranged from 12 to 82 years. No additional adverse reactions were identified to those reported in the severe asthma trials.

Systemic Reactions, including Hypersensitivity Reactions

In the trial, no systemic allergic (type I hypersensitivity) reactions were reported. Other systemic reactions were reported by 1 (2%) patient in the group receiving 300 mg of NUCALA and no patients in the placebo group. The reported manifestation of other systemic reaction was multifocal skin reaction experienced on the day of dosing.

Injection Site Reactions

Injection site reactions (e.g., burning, itching) occurred at a rate of 7% in patients receiving 300 mg of NUCALA compared with 4% in patients receiving placebo.

6.5

Immunogenicity

In adult and adolescent patients with severe asthma receiving NUCALA 100 mg, 15/260 (6%) had detectable anti-mepolizumab antibodies. Neutralizing antibodies were detected in 1 patient with asthma receiving NUCALA 100 mg. Antimepolizumab antibodies slightly increased (approximately 20%) the clearance of mepolizumab. There was no evidence of a correlation between anti-mepolizumab antibody titers and change in eosinophil level. The clinical relevance of the presence of anti-mepolizumab antibodies is not known. In the clinical trial of children aged 6 to 11 years with severe asthma receiving NUCALA 40 or 100 mg, 2/35 (6%) had detectable anti-mepolizumab antibodies during the initial short phase of the trial. No children had detectable anti-mepolizumab antibodies during the long phase of the trial.

In patients with CRSwNP receiving NUCALA 100 mg, 6/196 (3%) had detectable anti-mepolizumab antibodies. No neutralizing antibodies were detected in any patients with CRSwNP.

In patients with EGPA receiving 300 mg of NUCALA, 1/68 (<2%) had detectable anti-mepolizumab antibodies. No neutralizing antibodies were detected in any patients with EGPA.

In adult and adolescent patients with HES receiving 300 mg of NUCALA, 1/53 (2%) had detectable anti-mepolizumab antibodies. No neutralizing antibodies were detected in any patients with HES.

The reported frequency of anti-mepolizumab antibodies may underestimate the actual frequency due to lower assay sensitivity in the presence of high drug concentration. The data reflect the percentage of patients whose test results were positive for antibodies to mepolizumab in specific assays. The observed incidence of antibody positivity in an assay is highly dependent on several factors, including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.

6.6 Postmarketing Experience

In addition to adverse reactions reported from clinical trials, the following adverse reactions have been identified during postapproval use of NUCALA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, or causal connection to NUCALA or a combination of these factors.

Immune System Disorders

Hypersensitivity reactions, including anaphylaxis.

7 DRUG INTERACTIONS

Formal drug interaction trials have not been performed with NUCALA.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women with asthma exposed to NUCALA during pregnancy. Healthcare providers can enroll patients or encourage patients to enroll themselves by calling 1-877311-8972 or visiting www.mothertobaby.org/asthma.

Risk Summary

The data on pregnancy exposure are insufficient to inform on drug-associated risk. Monoclonal antibodies, such as mepolizumab, are transported across the placenta in a linear fashion as pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimester of pregnancy. In a prenatal and postnatal development study conducted in cynomolgus monkeys, there was no evidence of fetal harm with IV administration of mepolizumab throughout pregnancy at doses that produced exposures up to approximately 9 times the exposure at the maximum recommended human dose (MRHD) of 300 mg subcutaneous (see Data). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Disease-Associated Maternal and/or Embryofetal Risk: In women with poorly or moderately controlled asthma, evidence demonstrates that there is an increased risk of preeclampsia in the mother and prematurity, low birth weight, and small for gestational age in the neonate. The level of asthma control should be closely monitored in pregnant women and treatment adjusted as necessary to maintain optimal control.

Data

Animal Data: In a prenatal and postnatal development study, pregnant cynomolgus monkeys received mepolizumab from gestation Days 20 to 140 at doses that produced exposures up to approximately 9 times that achieved with the MRHD (on an AUC basis with maternal IV doses up to 100 mg/kg once every 4 weeks). Mepolizumab did not elicit adverse effects on fetal or neonatal growth (including immune function) up to 9 months after birth. Examinations for internal or skeletal malformations were not performed. Mepolizumab crossed the placenta in cynomolgus monkeys. Concentrations of mepolizumab were approximately 2.4 times higher in infants than in mothers up to Day 178 postpartum. Levels of mepolizumab in milk were ≤0.5% of maternal serum concentration. In a fertility, early embryonic, and embryofetal development study, pregnant CD-1 mice received an analogous antibody, which inhibits the activity of murine interleukin-5 (IL-5), at an IV dose of 50 mg/kg once per week throughout gestation.

(continued on next page)

8 USE IN SPECIFIC POPULATIONS (cont’d)

The analogous antibody was not teratogenic in mice. Embryofetal development of IL-5–deficient mice has been reported to be generally unaffected relative to wild-type mice.

8.2 Lactation Risk Summary

There is no information regarding the presence of mepolizumab in human milk, the effects on the breastfed infant, or the effects on milk production. However, mepolizumab is a humanized monoclonal antibody (IgG1 kappa), and immunoglobulin G (IgG) is present in human milk in small amounts. Mepolizumab was present in the milk of cynomolgus monkeys postpartum following dosing during pregnancy [see Use in Specific Populations (8.1)]. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NUCALA and any potential adverse effects on the breastfed infant from mepolizumab or from the underlying maternal condition.

8.4 Pediatric Use

Severe Asthma

The safety and efficacy of NUCALA for severe asthma, and with an eosinophilic phenotype, have been established in pediatric patients aged 6 years and older. Use of NUCALA in adolescents aged 12 to 17 years is supported by evidence from adequate and well-controlled trials in adults and adolescents. A total of 28 adolescents aged 12 to 17 years with severe asthma were enrolled in the Phase 3 asthma trials. Of these, 25 were enrolled in the 32-week exacerbation trial (Trial 2, NCT01691521) and had a mean age of 14.8 years. Patients had a history of 2 or more exacerbations in the previous year despite regular use of medium- or high-dose ICS plus additional controller(s) with or without OCS and had blood eosinophils of ≥150 cells/mcL at screening or ≥300 cells/mcL within 12 months prior to enrollment. [See Clinical Studies (14.1) of full prescribing information.] Patients had a reduction in the rate of exacerbations that trended in favor of NUCALA. Of the 19 adolescents who received NUCALA, 9 received 100 mg and the mean apparent clearance in these patients was 35% less than that of adults. The safety profile observed in adolescents was generally similar to that of the overall population in the Phase 3 studies [see Adverse Reactions (6.1)]

Use of NUCALA in pediatric patients aged 6 to 11 years with severe asthma, and with an eosinophilic phenotype, is supported by evidence from adequate and well-controlled trials in adults and adolescents with additional pharmacokinetic, pharmacodynamic, and safety data in children aged 6 to 11 years. A single, open-label clinical trial (NCT02377427) was conducted in 36 children aged 6 to 11 years (mean age: 8.6 years, 31% female) with severe asthma. Enrollment criteria were the same as for adolescents in the 32-week exacerbation trial (Trial 2). Based upon the pharmacokinetic data from this trial, a dose of 40 mg subcutaneous every 4 weeks was determined to have similar exposure to adults and adolescents administered a dose of 100 mg SC [see Clinical Pharmacology (12.3) of full prescribing information]

The effectiveness of NUCALA in pediatric patients aged 6 to 11 years is extrapolated from efficacy in adults and adolescents with support from pharmacokinetic analyses showing similar drug exposure levels for 40 mg administered subcutaneously every 4 weeks in children aged 6 to 11 years compared with adults and adolescents [see Clinical Pharmacology (12.3) of full prescribing information]. The safety profile and pharmacodynamic response observed in this trial for children aged 6 to 11 years were similar to that seen in adults and adolescents [see Adverse Reactions (6.1), Clinical Pharmacology (12.2) of full prescribing information]

The safety and effectiveness in pediatric patients aged younger than 6 years with severe asthma have not been established.

Chronic Rhinosinusitis with Nasal Polyps

The safety and effectiveness in patients aged younger than 18 years with CRSwNP have not been established.

Eosinophilic Granulomatosis with Polyangiitis

The safety and effectiveness in patients aged younger than 18 years with EGPA have not been established.

Hypereosinophilic Syndrome

The safety and effectiveness of NUCALA for HES have been established in adolescent patients aged 12 years and older. The safety and effectiveness in pediatric patients aged younger than 12 years with HES have not been established. Use of NUCALA for this indication is supported by evidence from an adequate and well-controlled study (NCT02836496) in adults and adolescents and an open-label extension study (NCT03306043). One adolescent received NUCALA during the controlled study and this patient and an additional 3 adolescents received NUCALA during the open-label extension study [see Clinical Studies (14.4) of full prescribing information]. The 1 adolescent treated with NUCALA in the 32-week trial did not have a HES flare or an adverse event reported. All adolescents received 300 mg of NUCALA for 20 weeks in the open-label extension.

8.5 Geriatric Use

Clinical trials of NUCALA did not include sufficient numbers of patients aged 65 years and older that received NUCALA (n = 79) to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. Based on available data, no adjustment of the dosage of NUCALA in geriatric patients is necessary, but greater sensitivity in some older individuals cannot be ruled out.

10 OVERDOSAGE

There is no specific treatment for an overdose with mepolizumab. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.

13 NONCLINICAL TOXICOLOGY

13.1 CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY

Long-term animal studies have not been performed to evaluate the carcinogenic potential of mepolizumab. Published literature using animal models suggests that IL-5 and eosinophils are part of an early inflammatory reaction at the site of tumorigenesis and can promote tumor rejection. However, other reports indicate that eosinophil infiltration into tumors can promote tumor growth. Therefore, the malignancy risk in humans from an antibody to IL-5 such as mepolizumab is unknown.

Male and female fertility were unaffected based upon no adverse histopathological findings in the reproductive organs from cynomolgus monkeys receiving mepolizumab for 6 months at IV dosages up to 100 mg/kg once every 4 weeks (approximately 20 times the MRHD of 300 mg on an AUC basis). Mating and reproductive performance were unaffected in male and female CD-1 mice receiving an analogous antibody, which inhibits the activity of murine IL-5, at an IV dosage of 50 mg/kg once per week.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Hypersensitivity Reactions

Inform patients that hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred after administration of NUCALA. Instruct patients to contact their physicians if such reactions occur.

Not for Acute Symptoms or Deteriorating Disease

Inform patients that NUCALA does not treat acute asthma symptoms or acute exacerbations. Inform patients to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with NUCALA.

Opportunistic Infections: Herpes Zoster

Inform patients that herpes zoster infections have occurred in patients receiving NUCALA and where medically appropriate, inform patients that vaccination should be considered.

Reduction of Corticosteroid Dosage

Inform patients to not discontinue systemic or inhaled corticosteroids except under the direct supervision of a physician. Inform patients that reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/ or unmask conditions previously suppressed by systemic corticosteroid therapy.

Pregnancy Exposure Registry

Inform women there is a pregnancy exposure registry that monitors pregnancy outcomes in women with asthma exposed to NUCALA during pregnancy and that they can enroll in the Pregnancy Exposure Registry by calling 1-877-311-8972 or by visiting www.mothertobaby.org/asthma [see Use in Specific Populations (8.1)]

Trademarks are owned by or licensed to the GSK group of companies. Manufactured by GlaxoSmithKline LLC Philadelphia, PA 19112

U.S. License Number 1727 Distributed by GlaxoSmithKline Research Triangle Park, NC 27709

MPLJRNA220004 August 2022 Produced in USA.

PRODUCT GUIDE CATEGORIES 32 All-in-One Diagnostic Solutions 32 ABI 34 Bone Health 34 Brain Function Assessment 36 Chemistry Analyzers 42 CLIA Waived 47 COVID-19 Testing 49 Cryosurgery 50 Diabetes/Blood Glucose 51 Exam Room Equipment 52 Flu and Respiratory 54 Hematology 58 Laboratory Services 60 Strep Tests 62 Syndromic Testing 64 Toxicology 64 Urinalysis 66 Women’s Health

ALL-IN-ONE DIAGNOSTIC SOLUTIONS

OPTIMIZE PRODUCTIVITY AND EXPAND YOUR PRACTICE

From

MedPod

The Medpod Medical Cart optimizes productivity and load balancing by enabling access to remote physicians during high volume periods or to reach low-density populations. Medpod’s proprietary software integrates with a wide range of professional medical devices and gives the remote provider control of the devices to conduct an examination that is on par with a faceto-face visit. Patient images, audio and data can be captured, annotated, tagged and uploaded in real-time or stored and forwarded into the EHR by either remote or local provider.

View Brochures, Videos & More at POR.io Enter Number 2207 in the Search Area

DEFINING MOBILE TELEDIAGNOSTICS

From

With the ability to deploy into a medical office in less than 2 minutes, MobileDoc is the ultimate portable practice. Revolutionary in its compact and mobile design, MobileDoc integrates best-in-class professional medicalgrade devices with state-of-the-art HD video and EHR connectivity.

2207 2208

MedPod

Physicians can provide care remotely that is on par or better than a face-to-face visit, including conducting basic exams, checking vitals, and performing specialty testing—shattering the boundaries of traditional care.

View Brochures, Videos & More at POR.io Enter Number 2208 in the Search Area

2209

PAD TESTING SYSTEMS IDEAL FOR PRIMARY CARE TO VASCULAR SPECIALISTS

From Newman Medical

Your patients Trust You to find their PAD

• You have many high risk patients, including anyone over 65 or diabetics or smokers

• Even if they are unaware of their PAD, 25% will have a heart attack or stroke within 5 years if not managed

• Patients often mistake symptoms of PAD for arthritis.

simpleABI Cuff-Link systems are easy to learn and use

• Push button remote, automatic calculations/waveforms

• PC based – reports are easy to save and share

Excellent Value and Reimbursements

• One test per week pays off system in less than one year

• Medicare reimbursements range from $80 to $220 depending on location and test

View Brochures, Videos & More at POR.io Enter Number 2209 in the Search Area

32 | PHYSICIANS OFFICE RESOURCE

PRODUCT FEATURE PRODUCT FOCUS ABI

Sign up at PhysiciansOfficeResource.com/home/contact/ Physicians Office Resource Invites You to GO ELECTRONIC! Sign up for our monthly eNewsLetter and get Physicians Office Resource delivered to your Inbox! Physicians office Resource Resources for You, Your Patients, & Your Practice THE PERFECT PAIR OSOM TRICHOMONAS TEST OSOM BVBLUE TEST PAGE 4 Respiratory Viruses and Infections: Making the Right Diagnosis Page Financial Considerations Unique to U.S.Physicians 2022 Issue 10

2210

WHY BINDEX® IS A GAME-CHANGER IN OSTEOPOROSIS DIAGNOSTICS.

From Bindex Medical

Comparable to DXA

Extensive clinical research has proven Bindex to be 90% accurate in detecting osteoporosis. It can replace nearly 70% of DXA scans for patients with suspected osteoporosis.

Fast and effective Using safe pulse-echo ultrasound to measure cortical bone thickness, Bindex analyzes bone density in just seconds.

Easy to use anywhere Lightweight and pocket-sized, Bindex allows patients to receive onthe-spot bone density scans in doctors’ offices, hospitals and clinics and at home.

View Brochures, Videos & More at POR.io Enter Number 2210 in the Search Area

BRAIN FUNCTION ASSESSMENT

EARLIER DETECTION OF MEMORY LOSS, DEMENTIA AND OTHER COGNITIVE DISORDERS

From

Morningside Medical

Standard cognitive screening tools like MMSE/ MOCA are exactly that; screening tools. The technology is there to test the patients that fail these screening tools right in your office. Get clinically relevant information about your patients’ brain performance, while generating additional reimbursement for the practice, leading to earlier diagnosis and more accurate referrals.

Aids in clear diagnosis • Strong Reimbursement • Improves Patient Outcomes • Easy for any staff to perform • Cognitive Testing / Mental Health • Sudomotor Function / Neuropathy • Vestibular Testing / Fall Prevention • Autonomic Function / Cardiovascular Risk

View Brochures, Videos & More at POR.io Enter Number 2211 in the Search Area

2211

2212

MEMORY LOSS BIOMARKERS TO AID IN DIAGNOSIS IN PRIMARY CARE PRACTICES

From

Evoke Neuroscience

The eVox® System is an FDA 510(k) cleared medical device to aid primary and specialty care physicians in diagnosis of memory loss and other cognitive disorders. eVox® measures memory loss biomarkers that may aid in detecting memory loss sooner, identifying the root cause of memory loss, and performing a differential diagnosis. eVox® procedures are performed in-office and are reimbursable by Medicare and commercial payers.

View Brochures, Videos & More at POR.io Enter Number 2212 in the Search Area

34 | PHYSICIANS OFFICE RESOURCE

BONE HEALTH PRODUCT FEATURE PRODUCT FOCUS

2213 2214 2215

FULL

CHEMISTRY ANALYZERS

EASY, INTEGRATED WITH-PATIENT TESTING I-STAT SYSTEM

From Abbott Point of Care

Easy, Integrated With-Patient Testing i-STAT System from Point of Care at Abbott

The handheld i-STAT System offers a broad menu of diagnostic tests at the patient’s side in just minutes. With just a few drops of blood, the i-STAT System delivers real time, lab-accurate results for a wide range of tests, including chemistries, blood gas, coagulation, cardiac markers, and more. Minimize delays and wasted time with on-side tests. Easy, intuitive operation.

For intended use and complete product information, visit pointofcare.abbott.

For intended use and complete product information, visit pointofcare.abbott. For in vitro diagnostic use only. This material is intended for a U.S. audience only. i-STAT is a trademark of Abbott. Physician Office Resource i-STAT Product Description – US 3064.REV1 08/20

For in vitro diagnostic use only. This material is intended for a U.S. audience only. i-STAT is a trademark of Abbott. Physician Office Resource i-STAT Product Description — US 3064.REV1 08/20

View Brochures, Videos & More at POR.io Enter Number 2216 in the Search Area

From Abbott Point of Care

The Piccolo Xpress Chemistry Analyzer provides physician offices with lab-accurate results for a broad range of CLIAwaived general chemistry tests, including metabolic panels, lipids, live, and kidney function, and more with just 100 microliters of blood. Easy to use, the PIccolo Xpress provides results during a patient’s visit, accelerating treatment decisions, increasing efficiency, and supporting patient satisfaction. Automated quality control on every test helps ensure accuracy.

View Brochures, Videos & More at POR.io

Enter Number 2217 in the Search Area 2218

Full Complement of Piccolo Xpress® Chemistry

The Piccolo Xpress Chemistry lab-accurate results for tests, including metabolic with just 100 microliters results during a patient’s efficiency, and supporting every test helps ensure

EASYRA® BENCHTOP CHEMISTRY ANALYZER FOR PHYSICIAN OFFICES WITH LABORATORIES

From

Carolina Liquid Chemistries

When upgrading or starting a lab, look no further. With a moderately complex menu of 35 general chemistry and 14 urine drug screens, the EasyRA is well-suited for oncology, rheumatology, and multi-specialty practices needing a highspeed benchtop clinical chemistry analyzer. The EasyRA® offers photometric throughput of 240+ tests/hr (up to 480 tests/hr with ISE) and STAT samples in under 8 minutes. This all-in-one system is easy to learn and easy to operate.

View Brochures, Videos & More at POR.io

Enter Number 2218 in the Search Area

36 | PHYSICIANS OFFICE RESOURCE

FEATURE PRODUCT FOCUS

2216 PRODUCT

For in vitro diagnostic use only. This Piccolo Xpress is a registered trademark Physician Office Resource Piccolo COMPLEMENT OF CLIA-WAIVED BLOOD CHEMISTRY TESTS PICCOLO XPRESS® CHEMISTRY ANALYZER

TOXICOLOGY SCREENING SIMPLIFIED. Toxicology screening solutions for physician offices, pain management, treatment centers and laboratories testing 200+ patient samples/mo. IMMTOX ™ 270 BENCHTOP ANALYZER © 2022 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. COL-09575 v3 12/22 1. Clinical Laboratory Improvement Amendments (CLIA) / * SEFRIA Fentanyl Comprehensive toxicology menu now with 14 CLIA 1 categorized moderate complexity assays. Scan this QR code to view the ImmTox™ 270 product video MODERATE COMPLEXITY ASSAYS – FDA 510(K) CLEARED 6-acetylmorphine (6-AM Heroin metabolite) EDDP (Methadone metabolite) Amphetamine Fentanyl* Barbiturates Methamphetamine Benzodiazepines Opiates Benzoylecgonine (Cocaine metabolite) Oxycodone Buprenorphine Phencyclidine (PCP) Cannabinoids (THC) Tramadol CONTACT ABBOTT CLINICAL LAB SOLUTIONS 855-425-9428 | CLS_SALES@ABBOTT.COM 2219

CHEMISTRY ANALYZERS

ENVOY500+ DELIVERING PROVEN RESULTS IN CLINICAL CHEMISTRY

From EliTech

The fully automated Envoy500+ is designed to deliver the performance of a large floor model analyzer but provides the cost efficiency of a benchtop analyzer (TPH approx. 490). It enables accurate treatment decisions sooner. Envoy500+ delivers savings the laboratory requires with the following features positive sample and reagent identification, clot detection, liquid level sensing, dry ISE module, reusable glass cuvettes, and many more.

View Brochures, Videos & More at POR.io Enter Number 2220 in the Search Area

PENTRA C400 CHEMISTRY ANALYZER

From HORIBA Medical

One benchtop, not a whole lab! No water system, drain or special electrical connected required to operate the Pentra C400 chemistry analyzer. Now you can have the power of a floor model analyzer on the benchtop! The Pentra C400 chemistry system processes up to 420 tests/hr including ISEs and offers routine metabolic assays, TDMs, DAUs and Adulterants, HbA1c and Vitamin D tests. With 40 open channels, you can add much more for a complete menu to meet your practice needs.

View Brochures, Videos & More at POR.io Enter Number 2221 in the Search Area 2221

RX DAYTONA+

From Randox Laboratories

The RX daytona+ is a fully automated, benchtop, clinical chemistry analyzer capable of performing high quality testing, with a combined throughput of 450 tests per hour, for accurate results you can trust. The most versatile analyzer in its class, the RX daytona+ combines robust hardware and intuitive software with the world leading RX series test menu for unrivaled performance, with direct HbA1c testing capabilities.

View Brochures, Videos & More at POR.io Enter Number 2222 in the Search Area

38 | PHYSICIANS OFFICE RESOURCE PRODUCT FEATURE PRODUCT FOCUS

2220

2222

2223

2224

CHEMISTRY ANALYZERS

RX IMOLA

From HORIBA Medical

The RX imola is a cost-effective system that delivers consistent high-quality results. Capable of handling the workload of a medium to high throughout laboratory and a combined throughput of 560 tests per hour, the RX imola provides rapid, comprehensive testing on a small footprint analyzer when it matters most, with direct HbA1c testing capabilities.

View Brochures, Videos & More at POR.io Enter Number 2224 in the Search Area

SCREENING SIMPLIFIED ABBOTT’S IMMTOX 270 BENCHTOP ANALYZER NOW WITH 14 ASSAYS CLIA CATEGORIZED AS MODERATE COMPLEXITY

TOXICOLOGY

2225

From Abbott

The ImmTox270 benchtop analyzer offers comprehensive toxicology screening solutions for physician offices, treatment centers and independent laboratories.

Broad test menu with over 20 assays to choose from including 14 that are now available as moderately complex.

With complete laboratory solutions from consultation to licensure, and compliance the Abbott Clinical Laboratory Solutions team has you covered.

View Brochures, Videos & More at POR.io Enter Number 2225 in the Search Area

TOXICOLOGY URINE DRUG SCREENING REAGENTS

From Abbott

Prescription drug misuse and illicit drug abuse is a growing public health challenge in this country. Building a test profile that covers highly misused drugs has never been so vital. With over 20 relevant assays to choose from Abbott’s suite of Immunalysis reagents allows you to easily screen for relevant substances. Our complete line of assays, calibrators, and controls enables you to implement an efficient drug screening program in office.

View Brochures, Videos & More at POR.io Enter Number 2226 in the Search Area

40 | PHYSICIANS OFFICE RESOURCE PRODUCT FEATURE PRODUCT FOCUS

CHEMISTRY ANALYZERS

Full Complement of CLIA-waived Blood Chemistry Tests Piccolo Xpress® Chemistry Analyzer from Abbott

FULL COMPLEMENT OF CLIA-WAIVED BLOOD CHEMISTRY TESTS PICCOLO XPRESS® CHEMISTRY ANALYZER

2227

The Piccolo Xpress Chemistry Analyzer provides physician offices with lab-accurate results for a broad range of CLIA-waived general chemistry tests, including metabolic panels, lipids, liver, and kidney function, and more with just 100 microliters of blood. Easy to use, the Piccolo Xpress provides results during a patient’s visit, accelerating treatment decisions, increasing efficiency, and supporting patient satisfaction. Automated quality control on every test helps ensure accuracy.

From Abbott Point of Care

The Piccolo Xpress Chemistry Analyzer provides physician offices with lab-accurate results for a broad range of CLIAwaived general chemistry tests, including metabolic panels, lipids, live, and kidney function, and more with just 100 microliters of blood. Easy to use, the PIccolo Xpress provides results during a patient’s visit, accelerating treatment decisions, increasing efficiency, and supporting patient satisfaction. Automated quality control on every test helps ensure accuracy.

For in vitro diagnostic use only. This material is intended for a U.S. audience only. Piccolo Xpress is a registered trademark of Abaxis, Inc. and distributed by Abbott Point of Care Physician Office Resource Piccolo Product Description – US 3065.REV1 08/20

View Brochures, Videos & More at POR.io

Enter Number 2227 in the Search Area

DC-LINEATE CALIBRATION/ LINEARITY MATERIAL

From SEKISUI Diagnostics

The DC-Lineate is a unique, trilevel calibration/linearity material that is used in conjunction with assays for the quantitative determination of UIBC levels in clinical samples. The material is conveniently packaged in a 2 x 5 mL configuration for each of the three levels and is traceable back to the National Institute of Standards and Technology (NIST). It can be used on a broad range of clinical chemistry analyzers and has a shelf life up to 14-days after reconstitution.

View Brochures, Videos & More at POR.io

Enter Number 2228 in the Search Area

LAB-ACCURATE RESULTS FOR ACR AND HBA1C

From Abbott

With its compact size and panel of tests, the Afinion 2 system is ideal for point-of-care testing in physician offices, clinics, community health centers and hospital out-patient clinics. From just a small urine or fingerstick whole blood sample, labaccurate results for ACR and HbA1c are made available during the consultation.

View Brochures, Videos & More at POR.io

Enter Number 2229 in the Search Area

42 | PHYSICIANS OFFICE RESOURCE

2229 CLIA

PRODUCT FEATURE PRODUCT FOCUS

WAIVED

2228

Choice without compromise. Soa 2 delivers automated, objective, and accurate results across a growing menu of assays from respiratory infectious diseases to Lyme disease and GI infections. With its unique “Advance Result Technology” (ART), Soa 2 can provide results in as few as 3 minutes, helping you get through increasingly heavier workloads. With Soa 2, you no longer have to choose between accuracy and speed. *THESE TESTS ARE AVAILABLE FOR SALE IN THE USA UNDER EMERGENCY USE AUTHORIZATION. These tests have not been FDA cleared or approved, but have been authorized by the FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. These assays are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless authorization is terminated or revoked sooner. AD10102100EN00 (03/22) *Flu + SARS Antigen | *SARS Antigen | Inuenza A+B RSV | Strep A+ | Lyme | Campylobacter For more information, contact Quidel Inside Sales at 858.431.5814. 2230

2231

ACCURATE, ACTIONABLE RESULTS FROM THE LEADER IN POINT-OFCARE LIPID TESTING

From Abbott

The CLIA-waived Alere Cholestech LDX™ Analyzer is engineered for confidence, providing accurate, actionable, and readily accessible results that have set the standard in point-of-care lipid profile, cholesterol, and glucose testing. Results are easy to obtain. Fingerstick sampling and a small sample size (40μL) makes results less painful and time consuming.

View Brochures, Videos & More at POR.io Enter Number 2231 in the Search Area

BD VERITOR™ PLUS SYSTEM

From

BD Veritor™

The BD Veritor™ Plus System is a portable, easy-to-use, testing solution for SARS-COV-2*, Flu A+ B and other respiratory tract infections that delivers results in 15 minutes or less. It features two analysis modes that adapt to your workflow, online education tools, and optional reporting capabilities including the BD Synapsys™ Informatics Solution—making it the point-ofcare diagnostic tool you won’t want to be without.

*EUA authorized by FDA

View Brochures, Videos & More at POR.io Enter Number 2232 in the Search Area

2232

2233

BIOFIRE® FILMARRAY® SYSTEM EZ CONFIGURATION

From bioMérieux

The BIOFIRE® 2.0 EZ Configuration facilitates rapid, near-patient molecular diagnostic testing. It is designed to be used with a BIOFIRE respiratory diagnostic solution in CLIA-waived testing sites, including clinics and physician offices. The system enables decentralized molecular testing throughout a provider network and features a simplified and intuitive interface. The BIOFIRE 2.0 EZ Configuration accurately provides results in about 45 minutes with only two minutes of hands-on time.

44 | PHYSICIANS OFFICE RESOURCE CLIA WAIVED

View Brochures, Videos & More at POR.io Enter Number 2233 in the Search Area PRODUCT FEATURE PRODUCT FOCUS

2234

ACUCY INFLUENZA A&B TEST From Sekisui Diagnostics

The Acucy™ Influenza A&B Test is for the rapid, qualitative detection of influenza A and B viral nucleoprotein antigens from both nasal and nasopharyngeal swabs. Utilizing the Acucy™ Reader in either the point-of-care or laboratory setting, workflow flexibility is achieved with both Read Now and Walk Away features. The combination provides clinicians with standardized and definitive result interpretation.

View Brochures, Videos & More at POR.io Enter Number 2234 in the Search Area

OSOM ULTRA PLUS FLU A&B TEST

From Sekisui Diagnostics

Stronger Clinical Performance Takes Lateral Flow Testing To The Next Level. Providing superior rapid results at the point-of-care. Fast, easy, cost effective so you can test and treat in one visit.

• High Performance- Equivalent or exceeding the performance of reader devices, without the need for an instrument • Results in 10 minutes

• OSOM® Custom Care- Exceptional Support/Training by licensed medical technologists and experienced healthcare professionals

• Made in the USA

View Brochures, Videos & More at POR.io Enter Number 2235 in the Search Area

2236

2235

OSOM® ULTRA STREP A TEST From Sekisui Diagnostics

The OSOM® Ultra Strep A test is a color immunochromatographic assay intended for the qualitative detection of Group A Streptococcus antigen directly from throat swab specimens. Shown to be not statistically different than single swab culture. Sensitivity 95.7% and 100% Specificity. Includes two additional test sticks for External QC. CLIA Waived..

View Brochures, Videos & More at POR.io Enter Number 2236 in the Search Area

2023 BUYERS GUIDE | 45 CLIA WAIVED

PRODUCT FOCUS

2237

OSOM® BVBLUE® From Sekisui Diagnostics

The OSOM® BVBLUE® detects elevated vaginal fluid sialidase activity, an enzyme produced by bacterial pathogens associated with bacterial vaginosis including Gardnerella, Bacteroides, Prevotella and Mobiluncus. OSOM® BVBLUE® is more sensitive than Amsel criteria providing physicians with a more accurate diagnosis to treat and minimize serious health consequences such as early spontaneous preterm births and miscarriage.

View Brochures, Videos & More at POR.io Enter Number 2237 in the Search Area

OSOM® TRICHOMONAS RAPID TEST From Sekisui Diagnostics

The OSOM® Trichomonas Rapid Test is intended for the qualitative detection of Trichomonas vaginalis antigens from vaginal swabs or from the saline solution. The OSOM® Trichomonas Rapid Test is a CLIA-waived rapid test available today. OSOM® Trichomonas is more sensitive than wet mount due to the assay being able to detect viable and non-viable organisms which offers significant benefits to the patient and clinician alike.

View Brochures, Videos & More at POR.io Enter Number 2238 in the Search Area 2238

ULTRA HCG COMBO TEST From Sekisui Diagnostics

The OSOM® Ultra hCG Combo test is a simple immunoassay for the qualitative detection of human chorionic gonadotropin (hCG) in serum or urine for the early confirmation of pregnancy. Internal studies have confirmed that the OSOM® Ultra hCG Combo test does not have a false negative result from hCG variants providing physicians with a higher level of confidence.

View Brochures, Videos & More at POR.io Enter Number 2239 in the Search Area

46 | PHYSICIANS OFFICE RESOURCE CLIA WAIVED

PRODUCT FEATURE PRODUCT FOCUS

2239

2240

FIRST EVER CLIA WAIVED HEMATOLOGY ANALYZER

From Sysmex

Faster test results, clinical decisions and greater practice efficiency are coming to physicians’ offices with the first CLIA-waived CBC analyzer. Hematology diagnostics leader Sysmex is bringing more lab testing to the point of care. One of the most common blood tests can be conducted reliably and accurately on-site, in as few as three minutes. The device’s ease of use and innovative technology means in-house staff can operate it in just a few easy steps, without lengthy certification and training. The new Sysmex XW-100 will improve health care efficiency and patient care.

View Brochures, Videos & Mores at POR.io Enter Number 2240 in the Search Area

COVID-19 TESTING

BD VERITOR™ PLUS SYSTEM

From BD Veritor™

*EUA authorized by FDA

View Brochures, Videos & More at POR.io Enter Number 2241 in the Search Area

2241

2242

BIOFIRE® FILMARRAY® SYSTEM EZ CONFIGURATION

From bioMérieux

2023 BUYERS GUIDE | 47 CLIA WAIVED

View Brochures, Videos & More at POR.io Enter Number 2242 in the Search Area PRODUCT FOCUS

2243

COVID-19 TESTING

WHY COMPROMISE? FAST AND RELIABLE RESULTS ARE NOW DELIVERED AT THE POINT OF CARE.

From LumiraDx

Introducing the next generation in point-of-care diagnostics. With a growing menu of tests, LumiraDx uses a simple process that allows for more time with your patients by using microfluidic technology that delivers results in minutes. Learn more about rapid COVID-19 diagnostic solutions for your physician office at LumiraDx.com.

View Brochures, Videos & More at POR.io Enter Number 2243 in the Search Area

CARESTART™ COVID-19 ANTIGEN TEST

From Mercedes Scientific®

This point-of-care (POC) designated test is one of the top-used amongst our customers.

Features/Benefits:

• CLIA WAIVED

• Results within 15 minutes

• Anterior nasal swab specimen collection

• Detects SARS-CoV-2 nucleocapsid protein antigen

• 87.2% sensitivity and 100% specificity

This test is not FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories.

View Brochures, Videos & More at POR.io Enter Number 2244 in the Search Area

2244 2245

SOFIA® 2 FLUORESCENT IMMUNOASSAY ANALYZER AND RAPID DIAGNOSTIC TEST KITS

From Quidel

Sofia® 2 Fluorescent Immunoassay Analyzer and Rapid Diagnostic Test Kits Sofia 2 takes rapid testing to a new level. Proven lateral-flow technology and advanced fluorescent chemistry are all integrated into this small benchtop analyzer which can be used in any point-of-care setting. Sofia 2 kits are easy to use and adaptable to any healthcare setting. Excellent performance, objectivity, quality control, LIS capabilities, and an expanding test menu make Sofia 2 the perfect solution for the physician’s office laboratory.

View Brochures, Videos & More at POR.io Enter Number 2245 in the Search Area

48 | PHYSICIANS OFFICE RESOURCE

PRODUCT FEATURE PRODUCT FOCUS

2246

HISTOFREEZER® FLEX

From CryoConcepts

This canister-based devices is the latest advance in portable cryosurgery for the physician office. Its advanced design give doctors the option of using cones or buds to deliver the cryogen to the treatment site. There is no risk of cryogen splattering during treatment and our cryogen stays colder versus other products on the market which lead to better first time outcomes.

View Brochures, Videos & More at POR.io

Enter Number 2246 in the Search Area

CRYOLAB® MEDICAL From CryoConcepts

CryoLab is a desk-top sized unit that delivers cryogen and employs pre-set spray times to ensure safe and effective treatment. Our lighted wand can spray the cryogen from any direction making it easier to treat all locations on the patient. CryoLab® can dispense nitrous oxide or carbon dioxide allowing physicians to treat cosmetically sensitive areas on the face, hands, and chest with less trauma and downtime.

View Brochures, Videos & More at POR.io

Enter Number 2247 in the Search Area

2247

CRYOMEGA® From CryoConcepts

This pen-like device is the perfect choice when low entry costs, portability, and precise delivery are critical to the practice. CryOmega® dispenses nitrous oxide – the coldest portable cryogen and the pinpoint tip allow physicians to effective treat the lesion site without harming healthy tissue.

View Brochures, Videos & More at POR.io Enter Number 2248 in the Search Area 2248

2023 BUYERS GUIDE | 49 CRYOSURGERY

PRODUCT FOCUS

2249

CRYOCLEAR®

From CryoConcepts

This is a new pen-like cryo devices that dispenses carbon dioxide which is perfect for superficial lesions such as sun spots, age spots, and shin tags. CryoClear® has enough gas to treat between 20 and 30 lesions depending on the size and type.

View Brochures, Videos & More at POR.io Enter Number 2249 in the Search Area

COMPREHENSIVE IN-OFFICE DIABETES TESTING WITH THE DCA VANTAGE® AND CLINITEK STATUS®+ ANALYZERS

From Siemens Healthineers

Siemens Healthineers DCA Vantage® and CLINITEK Status® family of analyzers provide hemoglobin A1c (HbA1c) and albuminto-creatinine ratio (ACR) testing at the point of care. Meet quality measures for A1c control and kidney disease check in minutes with CLIA-waived HbA1c testing and ACR1 ratio. Improve patient experience and overall outcome by providing actionable results in minutes.

1. Moderately complex on the DCA Vantage Analyzer. CLIA-waived on the CLINITEK Status+ Analyzer.

View Brochures, Videos & More at POR.io Enter Number 2250 in the Search Area

DIABETES/BLOOD GLUCOSE

ACCURATE, ACTIONABLE RESULTS FROM THE LEADER IN POINT-OFCARE LIPID TESTING

From Abbott

View Brochures, Videos & More at POR.io Enter Number 2251 in the Search Area 2251

50 | PHYSICIANS OFFICE RESOURCE CRYOSURGERY

PRODUCT FEATURE PRODUCT FOCUS

2250

2252

NOVA PRIMARY BLOOD GLUCOSE REFERENCE ANALYZER

From Nova Biomedical

The U.S. FDA has cleared Nova Primary as a blood glucose reference analyzer that fills the need for a new reference analyzer to replace the YSI STAT PLUS 2300 (YSI, Inc., Yellow Springs, OH). Manufacturers of blood glucose measuring devices and clinical diabetes researchers have relied on the YSI 2300 as a reference and correlation analyzer. However, YSI, Inc. no longer supports the analyzer, and its discontinuation has left a critical industry void.

With today’s FDA clearance, Nova Primary from Nova Biomedical is now available in the U.S. and worldwide.

View Brochures, Videos & More at POR.io Enter Number 2252 in the Search Area

LAB-ACCURATE RESULTS FOR ACR AND HBA1C

From Abbott

With its compact size and panel of tests, the Afinion 2 system is ideal for point-of-care testing in physician offices, clinics, community health centers and hospital out-patient clinics. From just a small urine or fingerstick whole blood sample, lab-accurate results for ACR and HbA1c are made available during the consultation.

View Brochures, Videos & More at POR.io Enter Number 2253 in the Search Area

2253

2254

EXAM ROOM EQUIPMENT

THE BREWER BASIC EXAM TABLE

From Brewer

Full featured, entry-level exam table design. The Brewer Basic Exam Table features a pneumatic cylinder, seamless upholstery, and the largest storage capacity available. We invite you to compare features, price, warranty and you will find the Brewer Basic Exam Table is clearly the best entry level exam table available.

2023 BUYERS GUIDE | 51

GLUCOSE

DIABETES/BLOOD

View Brochures, Videos & More at POR.io Enter Number 2254 in the Search Area PRODUCT FOCUS

2255

BREWER’S ACCESS™ HIGH-LOW EXAM TABLE

From

Brewer

Design provides an 18” profile in the seated position to allow level transfer from standard wheelchair heights, complete with upright seat back and safety grab bars to simplify reliable patient transfers. The system also offers abundant storage capacity with Brewer’s signature pass-through drawer system and it is backed by Brewer’s standard 3-year warranty.

View Brochures, Videos & More at POR.io Enter Number 2255 in the Search Area

BREWER’S FLEX™ ACCESS EXAM TABLE

From Brewer

Step up to power table performance for less with Brewer’s Flex™ Access Exam Table. Industry-leading 700-lb. patient weight capacity, unique safety features and unmatched ergonomic patient access maximize your clinical efficiency and ROI. A streamlined footprint and optional upgrades like safety grab bars, stirrups, and pass-through work surface provide ultimate flexibility for your practice.

View Brochures, Videos & More at POR.io Enter Number 2256 in the Search Area

2257

FLU

2256

AND RESPIRATORY

WHY COMPROMISE? FAST AND RELIABLE RESULTS ARE NOW DELIVERED AT THE POINT OF CARE.

From LumiraDx

52 | PHYSICIANS OFFICE RESOURCE

EXAM ROOM EQUIPMENT

View Brochures, Videos & More at POR.io Enter Number 2257 in the Search Area PRODUCT FEATURE PRODUCT FOCUS

2258

FLU AND RESPIRATORY

SOFIA® 2 FLUORESCENT IMMUNOASSAY ANALYZER AND RAPID DIAGNOSTIC TEST KITS

From Quidel

View Brochures, Videos & More at POR.io Enter Number 2258 in the Search Area

ACUCY INFLUENZA A&B TEST

From Sekisui Diagnostics

View Brochures, Videos & More at POR.io Enter Number 2259 in the Search Area 2259

2260

OSOM ULTRA PLUS FLU A&B TEST From Sekisui Diagnostics

Stronger Clinical Performance Takes Lateral Flow Testing To The Next Level. Providing superior rapid results at the point-of-care. Fast, easy, cost effective so you can test and treat in one visit.

• High Performance- Equivalent or exceeding the performance of reader devices, without the need for an instrument

• Results in 10 minutes

• OSOM® Custom Care- Exceptional Support/Training by licensed medical technologists and experienced healthcare professionals

• Made in the USA

View Brochures, Videos & More at POR.io

2023 BUYERS GUIDE | 53

Enter Number 2260 in the Search Area PRODUCT FOCUS

RELIABLE DETECTION OF STREP A, FLU A, FLU B AND RSV

From Cepheid

Cepheid’s GeneXpert Xpress® brings standardized molecular testing to any healthcare setting. Employing the highly accurate and easy to use lab in a cartridge technology in every GeneXpert system, the GeneXpert Xpress® is a true on-demand walkaway testing system that provides accurate and reliable detection of Strep A, Flu A, Flu B and RSV. Two or four-module configurations save valuable bench space and reduce the need for multiple testing platforms.

View Brochures, Videos & More at POR.io Enter Number 2262 in the Search Area

BD VERITOR™ PLUS SYSTEM

From BD Veritor™

*EUA authorized by FDA

View Brochures, Videos & More at POR.io Enter Number 2261 in the Search Area

2263

2262

HEMATOLOGY

CELL-DYN EMERALD 22 HEMATOLOGY ANALYZER

From Abbott

The CELL-DYN Emerald 22 is a full performance 5-part hematology analyzer for smaller clinical laboratories seeking productivity in smaller spaces.

Benefits:

• Compact Design - To conserve valuable workspace.

• Small and Powerful - Includes a numeric keypad entry, reagent tray, and integrated color touchscreen monitor.

• Easy and Automated - Barcoded reagents and touch-free scheduled daily maintenance, startup and shutdown.

• Online product training - Self-pace training available 24x7 on the Abbott’s Hematology Academy.

View Brochures, Videos & More at POR.io Enter Number 2263 in the Search Area

54 | PHYSICIANS OFFICE RESOURCE

2261 FLU AND RESPIRATORY

PRODUCT FEATURE PRODUCT FOCUS

2264

TURN SMALL PLACES INTO SMART SPACES

From Abbott

With reduced budgets, shrinking laboratory space and staffing challenges, many laboratories need a solution that lets them work smarter with less. The CELL-DYN Emerald 22 AL is a full performance, automated optical 5-part differential analyzer that delivers smarter results for small to midsize clinical laboratories.

• Compact Design

• Walkaway Functionality

• Ease Of Use

• Smart Safety Features

View Brochures, Videos & More at POR.io

Enter Number 2264 in the Search Area

MICROS HEMATOLOGY ANALYZER WITH 3-PART DIFFERENTIAL PLUS THE LITEDM

From HORIBA Medical

Is it viral or bacterial? A CBC with 3-part differential can provide the clues to help distinguish between viral and bacterial infections before you decide to treat. The Micros 60 Hematology analyzer provides a CBC with 3-part Diff result in less than 60 seconds using only 10 µL of sample. Connect to the LiteDM Patient Data Management System for an affordable way to consolidate patient results to one report.

View Brochures, Videos & More at POR.io Enter Number 2265 in the Search Area

2265

2266

PENTRA 60 C+ HEMATOLOGY ANALYZER WITH 5-PART DIFFERENTIAL

From HORIBA Medical

Now you can have the same results hospitals and reference labs provide in a small, benchtop analyzer. The Pentra 60 C+ hematology analyzer provides a CBC with 5-part differential result using proprietary technology that ensures an accurate count and differential on the first run. Reduce repeats and reflex to the microscope with Pentra hematology technology.

View Brochures, Videos & More at POR.io

Enter Number 2266 in the Search Area

2023 BUYERS GUIDE | 55 HEMATOLOGY

PRODUCT FOCUS

2267

HEMATOLOGY

TESTING

FIRST EVER CLIA WAIVED HEMATOLOGY ANALYZER

From Sysmex

View Brochures, Videos & Mores at POR.io Enter Number 2267 in the Search Area

MADE EASY From Sysmex

Designed for labs testing up to 25 samples per day, the Sysmex pocH-100i™ has the smallest footprint of any analyzer on the market. The instrument requires only 15uL of whole blood for reporting of 17 clinical parameters, including a 3-part WBC Differential. It is ideal for urgent care, physician office lab, small clinic, or any outpatient setting where a point of care CBC is needed.

View Brochures, Videos & More at POR.io Enter Number 2268 in the Search Area 2269

2268

NOW IT’S MORE THANK JUST A BLOOD TEST From Sysmex

With its simplified operation, the Sysmex XP-300™ is ideal for clinics and physician office labs. It provides a CBC with 17 different parameters, including a 3-part WBC Differential. The XP300+M combines the accuracy and reliability of a Sysmex CBC with the agility of Medicus Middleware. Features include EMR connectivity, instrument interfaces and a QC module.

View Brochures, Videos & More at POR.io Enter Number 2269 in the Search Area

56 | PHYSICIANS OFFICE RESOURCE

HEMATOLOGY

PRODUCT FEATURE PRODUCT FOCUS

RIGHT SIZE. RIGHT PERFORMANCE. THE RIGHT FIT FOR YOUR LABORATORY. CELL-DYN EMERALD 22 CELL-DYN EMERALD CELL-DYN EMERALD 22 AL CELL-DYN RUBY LOWVOLUME LOWTOMIDVOLUME MIDVOLUME o Support diverse test volumes o Technological sophistication for routine and specialized testing o Commutable results A suite of harmonized hematology solutions to meet the needs of your laboratory © 2022 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. CELL-DYN Ruby and CELL-DYN Emerald 22 AL are Class I laser products. For in vitro diagnostic use only. ADD-142016-GBL-EN 10/22 CORELABORATORY.ABBOTT/HEMATOLOGY 2271 2272 2273 2270

2274

MEDICUS LIS

From Medicus

LIS

If you are considering in-house lab testing, including Covid-19 testing and required reporting to state agencies, connecting Lab to LIS and EHR makes the process of test orders to completed results much easier. Providers receive test results posted to patient charts in real-time, expediting patient care, saving time, money and even preparing for lab test reimbursement goals. Link Your Lab with Medicus LIS today! Contact us: 888-643-8081 sales@medicuslis.com

View Brochures, Videos & More at POR.io Enter Number 2274 in the Search Area

MAKE LABORATORY COMPLIANCE AND INSPECTION EASIER

From My Inspection

Make laboratory compliance and inspections easier by changing how you document, save and retrieve all information necessary to meet CLIA and accreditation regulations. With two unique electronic tools My Compliance Manual and MyInspection™ Software, the guesswork and tedious task of interpreting and documenting policy, procedure, forms, charts and logs is over. Your lab will be compliant, have less paper, and be inspection ready.

View Brochures, Videos & More at POR.io Enter Number 2275 in the Search Area

2275

SPIROMETRY

MD6300 MICRO SPIROMETER FULL FUNCTION LOW COST SPIROMETER

From Mirco Direct

The Micro Spirometer is the newest offering in the Micro Direct spirometer line. Specifically designed for situations where low cost, precision spirometry measurements are required, the Micro Spirometer is lightweight and portable making it suitable for the physician office. The Micro Spirometer features a large color touch screen that is icon driven. The Micro Spirometer is supplied with Device Studio. A PC software for producing printouts of tests results or for creating PDF reports for attachment to the patients’ EMR file.

View Brochures, Videos & More at POR.io Enter Number 2276 in the Search Area

58 | PHYSICIANS OFFICE RESOURCE

LABORATORY SERVICES

PRODUCT FEATURE PRODUCT FOCUS

2276

LumiraDx’s microfluidic technology provides speed without compromising sensitivity at the point of care.

lumiradx.com

The LumiraDx SARS-CoV-2 Ag Test and the LumiraDx SARS-CoV-2 Ab Test have not been cleared or approved by FDA, but have been authorized for emergency use by FDA under an EUA for use by authorized laboratories. The LumiraDx SARS-CoV-2 Ag Test has been authorized only for the detection of SARS-CoV-2 nucleocapsid protein. The LumiraDx SARS-CoV-2 Ab Test has been authorized only for detecting the presence of total antibodies to SARS-CoV-2. They have not been authorized for use to detect any other viruses or pathogens. The emergency use of these Tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic Tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

S-COM-ART 01806 R1

2277

Immediacy now comes with accuracy. Why compromise?

MD6000

MD6800

PNEUMOTRAC SPIROMETER A POWERFUL SOLUTION FOR PC-BASED SPIROMETRY

From Micro Direct

The Pneumotrac connects to your PC by USB and captures reliable tests results immediately using the Spirotrac 6 software. These results can be printed or shared easily with compatible EMR systems. The Pneumotrac features a highly accurate, extremely stable Fleisch pneumotrach and meets the latest 2019 ATS/ERS standardization of spirometry ensuring testing meets the most up-to-date guidelines. Real-time curves and new animated incentives encourage maximal patient performance and obtain prompt quality feedback using the latest test session/session acceptability, usability and repeatability criteria.

View Brochures, Videos & More at POR.io Enter Number 2278 in the Search Area

ALPHA SPIROMETER THE FUTURE OF DESKTOP SPIROMETRY

From Micro Direct

The Alpha features a highly accurate, extremely stable Fleisch pneumotrach and meets the latest 2019 ATS/ERS standardization of spirometry ensuring testing meets the most up-to-date guidelines. Performing a test is very easy using the large icon driven touch screen. A test quality grading system and live testing prompts give you confidence and peace of mind when performing the test. Reports are printed instantly using the fast, integrated printer or obtain an 8.5” x 11” printout via Device Studio software that is included with the Alpha.

View Brochures, Videos & More at POR.io Enter Number 2279 in the Search Area

STREP TESTS

RELIABLE DETECTION OF STREP A, FLU A, FLU B AND RSV From Cepheid

View Brochures, Videos & More at POR.io Enter Number 1071 in the Search Area

60 | PHYSICIANS OFFICE RESOURCE SPIROMETRY

2280 PRODUCT FOCUS

2278 2279

2281

SOFIA® 2 FLUORESCENT IMMUNOASSAY ANALYZER AND RAPID DIAGNOSTIC

TEST KITS

2282

From Quidel

View Brochures, Videos & More at POR.io Enter Number 2282 in the Search Area

OSOM® ULTRA STREP A TEST

From Sekisui Diagnostics

View Brochures, Videos & More at POR.io Enter Number 2283 in the Search Area

2283

2284

SYNDROMIC TESTING

BIOFIRE® FILMARRAY® TORCH From bioMérieux

The BIOFIRE® FILMARRAY® TORCH is a fully integrated, random, and continuous-access system designed to meet your laboratory’s syndromic infectious disease testing needs. The benchtop footprint of the BIOFIRE TORCH saves precious lab space, and its scalability meets high throughput demands. BIOFIRE® FILMARRAY® Link Software automatically uploads patient results. Fully compatible with all BIOFIRE® FILMARRAY® Panels intended for use in CLIA-moderate settings, the BIOFIRE TORCH helps you maximize efficiency and productivity.

View Brochures, Videos & More at POR.io Enter Number 2284 in the Search Area

62 | PHYSICIANS OFFICE RESOURCE PRODUCT FEATURE PRODUCT FOCUS

STREP TESTS

Cannabis for chronic pain…

shouldn’t

Introducing NEW CANNACEUTICA— a lab-tested, broad spectrum cannabis capsule Now available at Liberty dispensaries in Maryland Scan to learn more on ConnectRx These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. • Conducting one of the largest trials of cannabis in chronic pain in conjunction with the University of California, Irvine • Speciﬁcally formulated by a team of PhD scientists • Rigorous testing ensures batch-to-batch consistency • Every bottle comes with

Easy

so patients can

self-titrate to the dose that works for them 2285

be a pain

Dose Chart,

slowly and safely

2286

TOXICOLOGY SCREENING SIMPLIFIED ABBOTT’S IMMTOX 270 BENCHTOP ANALYZER NOW WITH 14 ASSAYS CLIA CATEGORIZED AS MODERATE COMPLEXITY

From Abbott

The ImmTox270 benchtop analyzer offers comprehensive toxicology screening solutions for physician offices, treatment centers and independent laboratories.

Broad test menu with over 20 assays to choose from including 14 that are now available as moderately complex.

With complete laboratory solutions from consultation to licensure, and compliance the Abbott Clinical Laboratory Solutions team has you covered.

View Brochures, Videos & More at POR.io Enter Number 2286 in the Search Area

TOXICOLOGY URINE DRUG SCREENING REAGENTS

From Abbott

View Brochures, Videos & More at POR.io Enter Number 2287 in the Search Area

2288

2287

URINALYSIS

COMPREHENSIVE IN-OFFICE DIABETES TESTING WITH THE DCA VANTAGE® AND CLINITEK STATUS®+ ANALYZERS

From

Siemens Healthineers

1. Moderately complex on the DCA Vantage Analyzer. CLIA-waived on the CLINITEK Status+ Analyzer.

View Brochures, Videos & More at POR.io Enter Number 2288 in the Search Area

64 | PHYSICIANS OFFICE RESOURCE PRODUCT FEATURE

TOXICOLOGY

PRODUCT FOCUS

2289 2290 2291 2292 2293 2294 2295 2296

2297

OSOM® BVBLUE® From Sekisui Diagnostics

View Brochures, Videos & More at POR.io Enter Number 2297 in the Search Area

OSOM® TRICHOMONAS RAPID TEST From Sekisui Diagnostics

View Brochures, Videos & More at POR.io Enter Number 2298 in the Search Area 2298

2299

ULTRA HCG COMBO TEST From Sekisui Diagnostics

66 | PHYSICIANS OFFICE RESOURCE WOMEN'S HEALTH

View Brochures, Videos & More at POR.io Enter Number 2299 in the Search Area PRODUCT FOCUS

Resilience + Passion

We understand it is crucial to immediately diagnose and treat vulvovaginal disorders which are linked to a broad range of associated health complications, from preterm birth to an increase in Sexually Transmitted Infections.1

The OSOM® BVBLUE® and OSOM® Trichomonas Tests are easy-to-use, CLIA-waived and produce accurate and objective results for two of the most common causes of vulvovaginal disorders so you can get the answers fast and your patients back to doing what they love.

Like you, we understand there is a patient behind every answer—and that’s what matters most.

For more information, call 800-332-1042, or visit us at osomtests.com

For more information, call 888-616-0537, or visit us at osomtests.com

We make diagnostics that matter

registered trademark of SEKISUI Diagnostics,

every result matters

trademark of

TRICHOMONAS TEST OSOM® BVBLUE® TEST

Brown,

Improving the

Population Health Management.

suppl

2020 THE PERFECT PAIR 2300 2301

LLC. Because

™ is a trademark of SEKISUI Diagnostics, LLC. BVBLUE® is a registered

Gryphus Diagnostics, LLC. OSOM®

Diagnosis

Vulvovaginitis.

Vol. 23,

DON’T MISS A MOMENT.

Rapid results lead to accurate

treatment

options, onsite in about an hour.

In the time it takes to send samples to a lab, you can test for multiple pathogens onsite, with results in about an hour. The bioMérieux syndromic testing approach uses multiplex PCR technology to test for a comprehensive grouping of targets, giving you accurate results, quickly. Streamline your testing to quickly provide your patients the appropriate treatment with BIOFIRE.

BIOFIRE® RESPIRATORY 2.1-EZ PANEL (EUA)*

For use with the BIOFIRE® FILMARRAY® 2.0 EZ configuration in CLIA-waived settings.

BIOFIRE® FILMARRAY® GASTROINTESTINAL PANEL**

For use in CLIA-moderate settings.

BIOFIRE® JOINT INFECTION PANEL†

For use in CLIA-moderate settings.

*This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; This product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and, The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. Product availability varies

by country. Consult your bioMérieux representative. biofiredx.com/family-medicine

BFR0002-1659-01 2302 2303 2304

Buyers Guide 2023

Resilience

Getting the most from this guide

MEDICAL CONFERENCES

JANUARY

JUNE

JULY

NOVEMBER

DIRECTORY

A

B

C

D

E

F

G

DIAGNOSTIC + DEVICE COMPANY DIRECTORY

J

K

L

M

N

O

Q

R

T

V

HEALTH AGENCY HOTLINES

GOVERNMENT ORGANIZATIONS

STATE MEDICAL ASSOCIATIONS

PRODUCT CATEGORIES

DOPPLERS

PRODUCT CATEGORIES

DIABETES

DEFIBRILLATORS

BATTLE TESTED IN EOS DISEASE

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

IMPORTANT SAFETY INFORMATION (cont’d)

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Reduction of Corticosteroid Dosage

Parasitic (Helminth) Infection

ADVERSE REACTIONS

USE IN SPECIFIC POPULATIONS

1 INDICATIONS AND USAGE

Maintenance Treatment of Severe Asthma

Limitations of Use

Maintenance Treatment of Chronic Rhinosinusitis with Nasal Polyps

1.3 Eosinophilic Granulomatosis with Polyangiitis

Hypereosinophilic Syndrome

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Acute Asthma Symptoms or Deteriorating Disease

Reduction of Corticosteroid Dosage

Parasitic (Helminth) Infection

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience in Severe Asthma

and Adolescent Patients Aged 12 Years and Older

Adverse Reaction

Pediatric Patients Aged 6 to 11 Years

6.2 Clinical Trials Experience in Chronic Rhinosinusitis with Nasal Polyps

6 ADVERSE REACTIONS (cont’d)

Adverse Reaction

Reactions

Injection Site Reactions

6.3 Clinical Trials Experience in Eosinophilic Granulomatosis with Polyangiitis

Systemic Reactions, including Hypersensitivity Reactions

Injection Site Reactions

6.4 Clinical Trials Experience in Hypereosinophilic Syndrome

Systemic Reactions, including Hypersensitivity Reactions

Injection Site Reactions

Immunogenicity

6.6 Postmarketing Experience

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy Pregnancy Exposure Registry

Risk Summary

Clinical Considerations